Assessing and improving the efficacy of cancer multi-disciplinary teams in urology by Jalil, Rozh
1 
 
Assessing and improving the Efficacy of Cancer Multi-
Disciplinary Teams in Urology 
 
Rozh Tayfoor Jalil 
 MBChB MRCSEd PgDip MEd FHEA 
 
 
 
 
Centre for Patient Safety and Service Quality 
Department of Surgery and Cancer 
Imperial College London 
A thesis submitted for the degree of Doctor of Medicine MD(Res) 
 
 
 
2014 
 
 
2 
 
Declaration of originality  
 
The work presented in this thesis is my own and all else has been appropriately referenced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Copyright Declaration 
 
The copyright of this thesis rests with the author and is made available under a Creative 
Commons Attribution Non-Commercial No Derivatives licence. Researchers are free to copy, 
distribute or transmit the thesis on the condition that they attribute it, that they do not use it 
for commercial purposes and that they do not alter, transform or build upon it. For any reuse 
or redistribution, researchers must make clear to others the licence terms of this work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
Acknowledgments 
 
 
I truly thank my both supervisors Dr Nick Sevdalis and Mr James Green for the great support 
they gave me throughout the last 2 years. I also thank Professor Charles Vincent and Ms 
Renata Samulnik for the great support from the CPSSQ. 
I thank all my colleagues in the office who have been supportive and helpful especially Dr 
Stephanie Russ who was always available to help and advice. 
Special thanks to each of Maria Ahmed, Tajana Soukup Acencao, Benjamin Lamb and 
Waseem Akhter for the help they have offered me to conduct these studies. 
I thank the R&D department at Whipps Cross University Hospital for funding my research 
and also would like to thanks all the members of the Urology department at Whipps for the 
great time I had. I really enjoyed working there and felt part of the team and without the 
training and the support I had especially from Mr John Peters and Mr Stuart Graham , it 
would have been more challenging to obtain a NTN in Urology in North London. 
I would like also to thank all who participated in my survey and interview studies. 
Thanks and appreciation to the MDT FIT project team at KCL and Mr Mark Kowalczuk for 
their help in obtaining the material helped in some of my studies. 
Finally, I thank my wife Korda for her support, understanding and flexibility during the 
period of my research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
Abstract  
 
Cancer care driven by a multidisciplinary team (MDT) meeting is mandatory in UK and has 
become the platform to discuss cancer cases in many countries worldwide.  
My aim in this research is to assess the functionality and efficacy of the MDT meeting in 
making and implementing decisions. Specifically, I aim to develop tools to evaluate how 
MDTs make clinical decisions and recommendations, understand the role of leadership 
within these teams and measure why MDT decisions may not get implemented in patient 
care.  
The introduction chapter presents an exploration of the evidence base available in the 
literature on the functionality of cancer MDTs with a focus on how to assess the efficacy of 
MDTs. In this chapter, I used an „input-process-outcome‟ framework as a systems approach 
to the MDT and its working. Chapter 2 is a systematic review of the existing evidence on 
MDT decision making and decision implementation across surgical specialties. Chapter 3 
focuses on urological cancers and retrospectively evaluates MDT decision making from the 
perspective of implementation of team decisions into patient care. Chapters 4 and 5 present 
the views of core MDT members on the efficacy of the MDT in addition to problems and 
shortcomings faced by the MDT and also suggestions for improvement. Chapter 6 presents 
analysis of a survey on how to improve the efficiency of MDT. Chapters 7 and 8 present data 
from studies that objectively assess MDT performance by developing and validating 
observational assessment tools.  
Finally, the discussion chapter reflects on the findings of this research and discusses their 
implications for future research and practice. 
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1 Introduction  
 
1.1 Cancer Multidisciplinary Teams MDT 
 
Multidisciplinary teams (MDTs) in the NHS cancer care have been instituted for almost 20 
years.
 
The rationale for MDT-driven care is that bringing together cancer specialists from a 
range of disciplines allows holistic and unbiased review of treatment options and optimisation 
of treatment pathways for patients.
 
This thesis focuses on cancer multidisciplinary cancer 
teams with particular attention to the functionality of such teams and how that is linked to the 
outcome. In this introductory chapter, I first review the definition and the history of MDTs; I 
then provide an overview of their role within the cancer care pathway using an „input-
process-outcome approach‟. 
 
The multidisciplinary team (MDT) is defined as a “group of people of different healthcare 
disciplines, which meets together at a given time (whether physically in one place, or by 
video or teleconferencing) to discuss a given patient and who are each able to contribute 
independently to the diagnostic and treatment decisions about the patient”.[1] The role of the 
MDT is defined as “The main mechanism to ensure truly holistic care for patients and a 
seamless service for patients throughout their disease trajectory and across the boundaries of 
primary, secondary and tertiary care”.[2] Nowadays, it has become a standard practice in the 
UK that treatment decisions for cancer patients are made within the context of MDT 
meetings.[3, 4]  
 
Before the early 1990s, only a small proportion of cancer patients were managed by MDT of 
cancer specialists in some hospitals.  In 1995, The Calman-Hine report set out plans to 
improve the delivery of cancer services within the UK National Health System (NHS) and 
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provided the corner stone for establishing the national standards for cancer care.[5] Between 
1996 and 1999, the UK Department of Health (DoH) produced a series of evidence-based 
documents aimed to establish national standards for cancer care. Most of the 
recommendations in Calman-Hine were first applied to breast cancer services, and have 
subsequently been reformed in services for other common cancers such as colorectal, lung, 
gastrointestinal and gynaecological cancers.[6-10] In 2000, the DoH introduced the NHS 
cancer plan [3], which mandated the process for the management of cancer in UK. Then in 
2004, the DoH published the Manual for Cancer Services. This document demonstrated that 
cancer services were meeting the Standards for Better Health. In 2010, the National Cancer 
Action Team (NCAT), published a document that set out the characteristics of effective 
cancer MDT meeting as identified by responses of over 2000 MDT members to a survey in 
2009 about MDT working.[11] 
Efforts have been undertaken to endorse and implement MDTs in UK,[1, 3] Europe, [12, 13] 
USA, Asia,[14] and Australia however in other countries like Canada, there was no 
documentation of its use and establishment until recently.[15] Other countries remain not to 
have an MDT or it is non-mandatory.[16] 
 
Within urology, there are tree defined levels of care – all arranged via MDTs: local care, 
specialist care and supra-specialist care. At each level of care, a different type of MDT is 
carried out – either local, specialist or a supra- regional MDT meetings to choose the best 
care and treatment pathway.[1] 
 
1.2 Appraising the quality and efficacy of the MDT  
In the UK, the MDT is subject to an annual review process known as the „peer review‟. The 
national annual cancer peer review programme is a requisite mechanism for assessment of 
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MDTs and a national quality assurance programme for cancer services. MDTs have to show 
their compliance with standard measures that are derived from tumour-specific improving 
outcomes. This programme involves 3 stages: Internally validated self-assessment, externally 
verified self-assessment and peer review visits. Each of the stages determines whether each 
measure has been achieved or not, and whether progress is being made towards achieving 
them. The standards set by the cancer peer review programme encompass structural features 
of MDT meetings such as organisation and the constitution of MDT (having the required 
expertise); their attendance and having protocols for referral and treatment; providing 
evidence on caseload demographics and auditing cancer specific survival. Other aspects of 
MDT functioning, however, such as the quality of leadership and chairing, teamwork and the 
clinical decision-making process are not covered in the programme. In addition, there is 
neither a framework for evaluating the decision making within the MDT nor for the 
implementation of these decisions. Overall, to date there has been no agreed way to evaluate 
the efficacy of the MDT meetings.[17] Nevertheless, data from the peer-review programme 
demonstrates wide variation between teams in adherence to national standards.[18, 19]  
 
1.3 Structure of the MDT meeting 
The framework of „Input-Process-Outcome/Output‟ has been used previously in evaluating 
healthcare and teamwork quality.[20] This concept was established in aviation were it 
permits expectations and theory about the relationship between team factors and their effect 
on team performance. A few of both generic and context specific Input-process-Output 
models of healthcare team effectiveness have been published in the literature.[21] Based on 
own research, below is the outline of what is considered to be the most important components 
of each individual domain of this process. 
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This concept was introduced into healthcare by Donabedian who built up on this into the 
„pillars and buttresses‟ of quality assurance.[22] Here, I have used this model in relation to 
cancer MDTs as it provides a useful mean to study teams in general, and the MDT in 
particular. In what follows, I review the Input-Process-Outcome model that consists of 
various elements, some of which affects how the MDT works. It should be noted, however, 
that this model is schematic. This means that some elements are not easily categorised and 
could fit in both Process and Output. For example, education, decision making or recruitment 
into clinical trials as elements of what a MDT meeting is meant to do and achieve. Such 
elements imply a continuous process that leads to specific outputs. I have explored these 
elements within the time frame and resources that were available for me as part of this thesis. 
The figure below (Figure1) illustrates the „Input-Process-Outcome‟ approach and the 
elements that constitute each stage.  
In the following chapters of this thesis, I have focused in depth on the elements of 
information, chairing and leadership, coordination, decision making, time and caseload, MDT 
recommendation and decision implementation – these are colour-coded green in the figure. 
The remaining elements have been included in a general discussion (colour-coded grey in the 
figure) that includes areas that have been the subject of research by others, such as 
preparation, technology and telemedicine, teamwork and decision making. Finally, there are 
also areas that remain unexplored/anecdotal and provide a niche for future research such as 
educational value of MDT meetings and communication (colour-coded white in the figure). 
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Figure 1: An Input-Process-Outcome approach to the cancer MDT 
 
 
1.3.1 Input 
 
i. The NHS cancer plan[3] In 2000, for the first time a major programme of action 
was set out linking prevention, diagnosis, treatment, care and research. This plan set 
out the first comprehensive strategy to tackle cancer. It was a document for the NHS, 
setting out the actions and milestones that would deliver rapid improvement in cancer 
care services.          
                                                                                                                                                                                                                                                                                                                                             
 
ii. Information and preparation:  Research so far has demonstrated that clinical 
decision-making by cancer MDTs is influenced by many factors including the 
attendance of key team members, the process of case discussion, the information 
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available when making decisions, team leadership, preparation for meetings, facilities 
and equipment, and the administrative process. Enough patient information should be 
available to the team to discuss and make a decision regarding a treatment option for a 
given patient. Lack of sufficient information or poor preparation has been shown to be 
barriers to reaching into a decision and re-discuss the case in the next meeting.[23, 24] 
In a recent national survey of more than 2000 MDT members commissioned by the 
NCAT, an emerged theme to the question of “What one thing would you change to 
make your MDT more effective?” was better preparation for meetings.[25] 
 
iii. Attendance: One of the aims of these cancer case discussion meetings is the 
multidisciplinary approach in decision making about cancer management. Although 
surgeons tend to dominate these meetings,[26] the contribution of the other team 
members is essential to reach into the best treatment available of every discussed 
patient. Poor attendance of a key member of the MDT has been reported to be a factor 
that hampers decision making. [24, 26] 
Research has further demonstrated that clinical decision-making by cancer MDTs is 
influenced by factors including the attendance of team members, the process of case 
discussion, the information available when making decisions, team leadership, 
preparation for meetings, facilities and equipment, and the administrative process of 
auctioning outcomes from meetings.[23] 
 
iv. Information Technology IT/ Video-conferencing: In modern medicine, 
information and communication technology plays an important role in enhancing 
health care services. Having video-conferencing facilities allows sharing of images 
and pathological slides between MDTs. In order to make an MDT fulfil its purpose, 
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all the core members should be present when weighing up treatment options for 
cancer cases. Due to time pressure and centralisation of services sometimes it is not 
possible for all members to be present physically at the meeting venue. Availability of 
telemedicine allows bridging this gap and it has shown that it saves time for MDT 
core members.[27] A randomised trial demonstrated that telemedicine was as good as 
face-to-face discussion in compliance with clinical guidelines.[28] Yet another theme 
that emerged from the NCAT survey into making the MDT more effective was 
“Better technology”. This has also been reiterated in my own interview study – see 
Chapter 4.[24] 
 
v. Staffing:   Core members of the MDTs are surgeons, radiologists, histopathologists, 
oncologists, clinical nurse specialists, other allied health professionals (as required), 
and multidisciplinary team coordinators.[29] There should also be a single named lead 
clinician for the MDT -a role often performed by surgeons, though not exclusively. 
Depending on the tumour site, other professionals will need to be members of the 
team.[30] 
1.3.2 Process  
 
i. Coordination:  MDTs are thought to improve communication and coordination 
between healthcare professionals when weighing up treatment options for cancer 
patients.[31] In order to achieve this improvement, the organisation and the setup of 
the meeting needs good coordination. Soon after establishing the concept of MDT 
meetings, a need for an MDT coordinator became apparent and essential to maintain a 
smooth running and coordinated meeting.[32] Research so far has demonstrated that 
clinical decision-making by cancer MDTs is influenced by many factors, amongst 
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them are preparation for meetings, facilities and equipment, and the administrative 
process of these busy and demanding meetings.[23]  
 
 
ii. Chairing and leadership:  The role of MDT chairperson is central to effective-
running of the meeting. In a survey conducted in 2009 of MDT members, 98% of the 
respondents agreed that good leadership is essential for effective team working.[25] 
The MDT chair exercises a broad range of functions and has key responsibilities. 
These include ensuring integrity of team functioning, achieving team cohesion and 
goals in a timely and effective manner. These functions can only be served in a setting 
of collaboration between different professionals on the team and in the contribution to 
decision making. A good working relationship between the chair, MDT co-ordinator 
and other team members is critical to the successful functioning of the team. 
In a leadership model, the leader has a unique role in the decision making process that 
is different from other team members.  
Furthermore, effective leadership occurs as the leader guides and facilitates the team 
towards reaching the goal (which is a clinically appropriate decision in a MDT 
meeting setting).[33] In order to achieve this, a leader must have the necessary skills. 
These skills for a MDT leader/chair have been summarised in „The Characteristics of 
an Effective Multidisciplinary Team (MDT)‟ document[34] that was produced by the 
NCAT as a result of a survey of the views of more than 2000 MDT core members and 
of stakeholders‟ on effective MDT working.[25] Although in most MDT meetings the 
chair is a doctor (often a surgeon), a question does exist whether nurses or other allied 
healthcare professionals could/should chair the meeting.[25, 35] 
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iii. Education:  In addition to the principal role of MDT meetings in discussing cancer 
cases and formulating a management plan for such patients, those meetings have a 
key role in personal development and training. Learning can be achieved from 
gathering information about patients when studying case notes. It can be gained by 
attending MDT meetings and from the interactive discussion.  These meetings can be 
vital resources for doctors in training, as well as for specialist nurses and even for 
senior healthcare professionals. Further, training opportunities are available to support 
individuals‟ roles. [11] Training can help each member of the team to function 
optimally especially in bringing the relevant information to the meeting that can 
contribute to the decision making process. 
 
 
iv. Time and caseload:  Most MDTs are held weekly.[35] Preparation for and 
attending the MDT meetings requires a considerable amount of time from all the 
members.[36] It has been estimated that, for each meeting hour, 2.4 pathology hours 
and 2 radiology hours are spent in preparation.[37] Currently, it is mandatory to 
discuss all new cancer patients in the MDT meeting.[38] However, a question exists 
to whether MDTs should focus on patients whose care is diﬃcult, rather than all 
patients. [24, 36] A national survey analysed by our group recently showed that the 
majority of MDT members across different tumour types agree that all cancer patients 
with recurrence and advanced disease should be discussed by MDT (for urology this 
was 79%).[39] Another recent study, however, showed that only a few of the patients 
with recurrent disease are actually re-discussed at the MDT meeting.[40] On the other 
hand, it has been argued that less complex cases take only a minimum time to discuss, 
so this might not be a worthwhile change.[41]  
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The number of cases discussed varies from specialty to specialty and even from a 
meeting to another in the same speciality,[42, 43] which may turn the meeting very 
busy and rushed. Some MDTs regularly discuss less than 10 patients (e.g., Head and 
Neck tumours) and in others the caseload can exceed 40 patients (e.g., urology). 
 
v. Teamwork:  With the introduction of MDTs, decisions in surgical oncology are made 
by these teams. It was the complexity and the sophistication of cancer management 
that led to the introduction of such multifaceted teams of experts. Fleissig and 
colleagues hypothesised that the MDT approach improves coordination, 
communication and decision making between healthcare professionals by bringing the 
experts together.[31] In one study, the initial treatment recommendations for 43% of 
the cases of women with breast cancer were changed following a second opinion of a 
multidisciplinary panel.[44] In addition to the clinical advantages of MDTs, it was 
also reported that it improves team working.[45] However, full contribution of all the 
MDT members is essential for effective teamwork.[31, 46] 
 
vi. Decision making:  The aim of an MDT approach is to ensure that the disease is 
accurately staged and decisions are evidence-based and patient-centred. The decision 
making process involves weighing up treatment options for patients after considering 
patients‟ clinical and non-clinical information in a “team of experts” approach with 
the contribution of all MDT members producing evidence based recommendations for 
treating all cancers.  
 
It has been shown that the MDT approach affects the diagnosis and management 
decisions in a significant number of patients with urological malignancies.[47] An 
important aspect of MDT-driven care is that the quality of how a MDT runs is likely 
associated with the quality of its decision-making – including whether the team is able 
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to make recommendations on first case presentation. Decisions are not always reached 
and factors that affect decision making are variable.[24] Recently successful attempts 
have been made by our research group to enhance and support decision making of 
cancer MDTs.[48] 
 
 
 
1.3.3 Outcome 
 
i. Communication:  MDTs are widely felt to improve communication between 
healthcare professionals when evaluating treatment options for cancer patients.[31] 
However, a recent Australian qualitative study by Rowlands and colleagues has 
shown that barriers still exist to effective communication among lung cancer MDT 
members[49]. 
 
A practising standard that has been set up is mandating that after a patient is given a 
diagnosis of cancer, the patient‟s general practitioner should be informed of the 
diagnosis by the end of the following working day.[30] This is a peer review measure 
and an audit of timeliness of notification to general practitioners of diagnosis of 
cancer should be conducted. A recent semi-structured interview study demonstrated 
that most GPs were dissatisfied with the timing of communication – which often 
exceeds the above standard.[50] 
 
ii. Clinical trials:  Randomised controlled clinical trials are recognised as the most 
reliable method for evaluating interventions in medicine and most importantly in 
Oncology. With the increasing pressure for a more systematic approach to healthcare 
delivery based on clinical and cost effectiveness, clinical trials play an important role 
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to achieve this. The capability of a clinical trial to deliver safe and valid results that 
are clinically significant and generalisable depends on the recruitment of sufficient 
numbers of patients.[51] Failure to recruit into trials, however, is common and has 
been widely reported in the literature. With the standardisation of MDT in cancer 
management pathway, evidence is consistently emerging on the benefits of this 
approach including its role in maximizing recruiting into clinical trials.[52, 53] One of 
the objectives of MDT working is to ensure that mechanisms are in place that support 
the entry of eligible patients into trials – hence this is a key outcome of MDT 
working.[1] 
 
iii. MDT recommendations and their implementation : Some recent evidence 
questions the optimal functioning of the MDT [23, 54-58] in particular, the ability of 
the team members to reach the best decision for the patient;[23, 56] whether the 
recommendations are appropriate;[26, 56, 59] and finally whether they get 
implemented into patient care subsequent to the team meeting. [56, 60-62] 
 
iv. Survival:  Improved survival is an ultimate aim and desired outcome of MDTs. 
Improving survival was one of the four aims behind setting out the NHS Cancer 
Plan.[3] There is some emerging evidence of the link between the introduction of 
MDT and survival. This evidence was lacking and anecdotal for some time but a large 
cohort study recently showed that the introduction of the MDT in the pathway of 
cancer care is associated with improved survival.[63] However as currently discussing 
all new suspected and diagnosed cancers by the MDT is mandatory in the UK, 
rigorous randomised control trials to further evaluate the link between MDT and 
cancer survival are understandingly difficult to organise.  
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v. Cost effectiveness: Cancer care is expensive. The cost of MDT working has not yet 
been properly evaluated, and cost-effectiveness is even further from being defined. It 
was estimated that multidisciplinary team meetings cost the NHS around £50m a year 
for preparation and a similar amount for attendance time.[17] Estimates so far range 
from £14.10 to £628.53 for each treatment plan.[64] Any assessment of the cost-
effectiveness of MDT working will have to take account upfront costs of setting up 
and running MDT meetings, as well as any other costs (in terms of time or expense) 
that occur later in the treatment pathway.  
 
 
1.4 Where are we in assessing the quality of MDT meetings? 
 
1.4.1 Assessing by clinical outcome 
 
Despite the increasing acceptance of MDTs internationally, there is little high level hard 
evidence for improved clinical outcomes (i.e., survival) as a direct influence of the 
introduction of cancer MDTs.[65-68] On the other hand, a recent study showed that the 
introduction of multidisciplinary care is associated with improved survival and reduced 
variation in survival among hospitals.[63] This was also concluded by earlier smaller 
studies.[69, 70] It has been reported that treatment of oral cancer patients in a specialist unit 
that has access to MDT, is associated with improving survival and also reduction in cancer 
recurrence rate.[71] 
Assessing the quality of cancer care will unavoidably involve measuring the outcome (i.e. 
survival) – although the complexity of cancer may mean that a direct link between MDT 
driven care and improved outcomes cannot be firmly established. 
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1.4.2 Assessing by the ability to make decisions 
 
My group‟s research has shown that not every patient discussed at the cancer MDT will have 
a management decision reached at that time point. Barriers to reaching a clear plan are 
variable and include: lack of clinical or staging information, lack of personal knowledge of 
patients, lack of information on co-morbidities, poor attendance by MDT members, 
disagreement or complex cases.[26] Some recent evidence also suggests that MDTs do not 
always function optimally.[23, 54-58] In particular, team decision-making processes and the 
ability of the team members to work together to reach the best decision for the patient.[23, 
56] The quality of decision making, the appropriateness of these decisions and the success in 
reaching a decision plan at the first presentation of the cases have been shown that they could 
comprise the quality of the MDT meeting.[23, 26, 56] 
 
1.4.3 Assessing by compliance with guidelines  
The team nature of the MDT ensures that care follows recognised guidelines. [72] It has been 
shown that the MDT model can improve adherence to guidelines.[73] On this basis, a 
particular MDT could be assessed on how consistent their decisions are to certain guidelines. 
However guidelines for every cancer and every stage do not exist. 
 
1.4.4 Assessing by decision implementation 
At MDT meetings, there is a discussion of patient‟s clinical details alongside detailed review 
of the radiological and pathological information within a context of a multidisciplinary 
experts in order to reach into a decision/recommendation that are then shared with the patient. 
Treatments are taken forward or changed if deemed inappropriate or declined by the patient. 
As the MDT decision is considered a decision of consensus of cancer experts, it is anticipated 
that it is the best available option(s) and thus it ought to be implemented. The MDT‟s 
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decision outcome for a discussed patient and the implementation of that same decision is thus 
a potential measure of the performance of that particular team.  
 
In light of the above, previous attempts to assess the quality of MDT have been made and 
implementation of team decisions into patient care has been used for this purpose.[60-62, 74] 
This measure to assess the MDT functioning has been used in some of the surgical specialties 
such as upper gastro-intestinal and lung cancer MDTs. However, the evidence comes from 
small scale studies and only a few of the surgical specialties have been studied to date. 
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Thesis Aims  
 
My aims in this thesis are  
 
1. To evaluate the available and generate evidence on the efficacy of MDT decision 
making and decision implementation (chapters 1, 2 and 3). 
2. To assess the views and experience of the MDT members (clinical and non-clinical) 
on the functionality of the MDT meeting (chapters 4 and 5). 
3. To explore the views of core MDT members on possible ways to improve the current 
functionality of the cancer MDT meeting (chapter 6). 
4. To develop methods for assessing the quality of the “input-process” parts of the MDT 
meeting by focusing on the important factors influencing the MDT outcome, i.e. 
information, teamwork and leadership (chapters 7 and 8). 
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2 Making and implementing MDT meeting decisions: Systematic review  
 
2.1 Chapter overview  
In this chapter, I present a systematic review of the current empirical research on the outcome 
of the MDT decisions (whether they have been implemented in practice), the factors that 
affect their implementation and the consequences of discordance. In the literature, two terms 
have been commonly used: an implemented decision is a „concordant‟ decision and a non-
implemented decision is a „discordant‟ decision. I will be using these terms throughout this 
thesis.  
 
As I mentioned in the previous chapter, there is no agreed consensus on the way to assess the 
MDT meetings with the exception of the „peer review‟ programme, which is merely to 
measure the structure and some functions of the team. The efficacy of the MDT meeting 
could be assessed by its outcomes including the implementation of the decisions reached by 
the MDT – this is the focus of this review.  
 
2.2 Aims  
The aim of this systematic review is to examine the literature on assessing the efficacy of 
cancer teams through the implementation of cancer MDT meeting decisions and the factors 
that enhance or impede effective decision implementation. I also examined the factors that 
influence MDT decision changing (i.e. discordant decisions) and the eventual outcome of the 
changed decisions, as well as the time delay from the MDT meeting decision to receiving the 
final treatment.  
37 
 
2.3 Methods 
I performed a systematic search of the literature of Embase, Medline, PsycINFO (using 
OvidSP), CINAHL, the Cochrane database and Pubmed. The free text and MeSH search 
terms used were variations of „„neoplasm‟‟, „„multidisciplinary” and „„decision”. The final 
search terms were a consensus agreement among the research team. 
Results were limited to human beings, English language and dates 1990 to May 2014 (the 
detailed search strategy is available in Appendix 2). I also hand-searched studies through 
consultation with experts in the field, study of reference lists of retrieved papers, existing 
reviews, guidelines and governmental documents.  
 
Retrieved titles and abstracts had to relate to decision making and implementation within 
context of multidisciplinary cancer teams. Articles had to provide data relating to 
management decisions of patients made by a MDT as well as data on implementation of these 
decisions. I applied these criteria to all the titles of the included articles.  
 
Both myself and another member of the research team (Sevdalis) reviewed the abstracts 
resulted from the title review. After reviewing 32.3%(n=80) of the abstracts jointly, the 
selection criteria were applied by both of us independently to the remaining abstracts. Inter-
reviewer agreement in article selection was calculated for the independently reviewed 
abstracts using Kappa 0.761(P<0.001) which indicated very good agreement. Disagreement 
was resolved by including the article in the full text review. 
It was intended to conduct a meta-analysis for the time delay of the implemented as 
compared to the non-implemented decisions. In order to undertake this, the corresponding 
authors of the relevant articles were contacted. Unfortunately there was no data available to 
conduct further analysis. 
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PRISMA is the preferred reporting method for systematic reviews. This was followed to a 
certain extent. However, as many of the checklist items were not applicable in this study type, 
it was not explicitly followed and mentioned. 
 
 
2.4 Results  
2.4.1 Study characteristics  
The search strategy retrieved 6166 titles (Figure 2). The application of the inclusion criteria 
excluded 6126 articles. Three articles were found by hand search and were included in the 
analysis. A final 13 articles resulted from reviewing the full text of the 43 included articles.  
Articles were from 4 countries: UK (n=7),[40, 74-80] France (n=3), [80-82] Germany (n=1), 
[83] and USA (n=2),[84, 85]. The articles represented 6 specialties: Upper gastro-Intestinal 
(n=4), [40, 74, 75, 80] Lung or Thoracic oncology (n=2),[82, 84] Colorectal (n=1), [78] Brain 
tumour (n=1),[83] Breast (n=2),[76, 79] Dermatology (n=1),[81] and one article studied 
various tumours[85]. The study design was retrospective in 8 studies[40, 77-81, 83, 84] and 
prospective in 5 studies.[74-76, 82, 85] 
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Figure 2: Systematic review study selection flow diagram 
 
 
 
2.4.2 Implementation of MDT decisions (Table 1) 
 
A total of 6405 out of 7059 decisions were analysed for implementation of MDT decisions 
(Bumm et al. and Petty et al.[80, 85] did not analyse reasons of discordance in MDT 
decisions). 
Overall, 9.4% (n=602) of the decisions were not implemented. The main reasons preventing 
the MDT decision to carry out into practice were: the availability of new information about 
the patient or a decline in patient‟s health; patient‟s disagreement with the MDT decision; 
unsuitability of the treatment due to patient‟s comorbidity. The breakdown of the reasons that 
drove non-implementation is presented in Figure 3. 
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Figure 3: Graph showing factors that impeded implementation of MDT decisions in the 
reviewed studies 
 
 
 
 
Furthermore, I also analysed the specialty variability in MDT decision implementation. 
Specialties differed in the rate of decision implementation. Lung/thoracic oncology reported 
the highest decision discordance whereas Gynaecology the lowest (Figure 4). 
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Figure 4: Graph showing specialty variation in MDT decision implementation 
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Table 1: Implementation and factors that impact on MDT decision discordance 
Author, 
Year 
Study design Study 
population 
Speciality Non-
implementation of 
MDT decision (%) 
Reason for non-implementation 
Blazeby et al. 
2006[75] 
Prospective 271 decisions. Upper GI 15.1% (n=41 
decisions) 
 43.9%  (n=18) patient co-morbid health issues. 
 34.2 % ( n=14) related to patient choice. 
 19.5 % ( n=8) more clinical information was 
available) e.g. metastatic disease discovered at 
time of surgery). 
2.4%  n=1, no apparent reason 
Bumm et al. 
2007[80] 
Retrospective Total N = 
6076 patients, 
807 decisions 
analysed for 
implementatio
n. 
Upper GI, 
oesophageal 
cancer. 
4% (n=32 decisions) Reasons for non-implementation were not 
analysed. 
Goolam-
Hossen et al. 
2011[74] 
 
Prospective 363 decisions 
 
Upper GI 
Cancer 
19.5% 
(n=71decisions) 
45.1% (n=32) co-morbidity 
33.8% (n=24) new clinical information 
available 
18.3% (n=13) patient refusal 
2.8% (n=2) no apparent reason 
Strong et al. 
2012[40] 
Retrospective 29( recurrent 
disease) 
Upper GI 
Cancer 
13.8% (n=4 
decisions) 
50% (n=2) declining health 
50% (n=2) patient preference 
Wood et al. 
2008[78] 
Retrospective 157 patients 
and 201 
decisions 
 
Colorectal 
cancer 
10% (20 decisions ) 45% (n=9) co-morbidities 
35% (n=7) patient‟s choice 
10% (n=2) new clinical information 
5% (n=1) doctor changed the decision 
5% (n=1) no apparent reson.0 
Osarogiagbon 
et al. 
2011[84] 
Retrospective 376 patients, 
454 decisions 
 
Thoracic 
oncology 
38% (n=171 
decisions) 
 61% (n=104) clinician decision( n=61 clinical 
contraindication, n=14 co-morbidities,  
n=11 insurance problems,  
n=11 stage discrepancy,  
n=7 poor performance status) 
19 %( n=32) patient loss to follow up care. 
15%(n=26) patient refusal 
5% (n=9) patient died before treatment 
Leo et al. 
2007[82] 
Prospective 344 patients, 
97 patients 
studied for 
decision 
implementatio
n 
 
Lung cancer 4.4% (n=15 
decisions) 
2% (n=7) refused treatment 
1.4% (n=5) co-morbidities prevented treatment 
0.3% (n=1) physician choice(doctor sought 
second opinion) 
13.3% (n=2) lost in the follow up 
Lutterbach et 
al. 2005[83] 
Retrospective Total N = 
1,516 patients. 
A random 
sample of 500 
patients was 
studied for 
decision 
implementatio
n 
 
Brain tumour. 9% (n=45 decisions) 57.8% (n=26) lack of progression  
11.1% (n=5) decline in the patient‟s general or 
neurological performance status between the 
MDT presentation and the initiation of the 
recommended treatment. 
31.1% (n=14) the treating physician found 
another local treatment to be more adequate. 
Palmer et al. 
2010[77] 
Retrospective  Total N = 535 
cases ( 509 
analysed for 
decision 
implementatio
n)  
Gynaecology 3% (n=15 decisions) 13.3% (n=2) co-morbidity,  
26.7% (n=4)patient did not attend,  
6.7% (n=1)patient referred to private sector,  
20% (n=3)patient choice,  
6.7% (n=1)new information  
26.7% (n=4) discretion of clinician (clinician 
not at MDT meeting) 
Caudron et al. 
2010[81] 
Retrospective 228 patients, 
349 
decisions(309 
analysed) 
Jan 2006- Dec 
Dermatology  12% (n = 36 
decisions) 
44.4% (n=1)6 patient refusal 
27.8 % ( n=10) patients died before treatment. 
13.9 % ( n=5) deterioration of general 
condition.                
11.1% (n=4) opposition of the treating doctor 
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2.4.3 The eventual outcome of non-implemented MDT decisions 
A few of the studies (n=3) analysed the outcome of non-adherence to the MDT meeting 
decisions.[74, 75, 83] Results showed that this led to patients go down the route of having a 
more supportive or „watchful waiting‟ treatment (Goolam-Hossen et al. 44/71 (62%); 
Blazeby et al. 25/41 (61%); Lutterbach et al. 26/45 (58%)). Six of these studies also analysed 
the factors that can influence the change in decision making in the MDT meetings (Table 2). 
 
 
Table 2: Factors that influence MDT decision changing 
  
Study Factors 
Wood et al. 
[78] 
Multivariate analysis exploring factors that might influence whether MDT treatment decisions changed after the 
meeting showed that treatment intent was a more important reason for not following the MDTs recommendation 
compared to being male or of older age. Decisions for colonic tumours were also more likely to change after the 
meeting than those made for patients with tumours of the rectum or anus after adjusting for gender, age and 
treatment intent. 
English et al. 
[76] 
The regression analysis showed that MDT decisions were significantly more likely to change in older than younger 
women and in those with finally proven malignant rather than benign disease. 
Goolam-
Hossen et al. 
[74] 
Of the 71 non-implemented treatment decisions, seven changed from an active treatment plan to another or to 
active surveillance and the remainder changed between palliative treatments or from a curative to a palliative 
treatment. 
Blazeby et al. 
[75]  
Discordance almost always arose from patients receiving a more conservative treatment than that originally 
planned. 
Multivariate analysis showed that diagnosis was a more important reason for not following the MDTs 
recommendation compared to being female or of older age. 
Osarogiagbon 
et al.[84] 
Whites were more likely to receive concordant care than black patients. Those with commercial insurance were the 
most likely to receive concordant care and those with no insurance, least likely. A slight majority of the uninsured 
received discordant care 
Leo et al.[82] It is of interest to note that the median age of discordant cases was significantly higher than the median age of 
concordant cases (74 versus 65 years, p _ 0.01). The rate of discordance was higher for supportive care (2/12, 
16.6%) and radiotherapy (1/14, 7.1%) compared chemotherapy (5/183, 2.7%) and surgery (4/93, 4.3%). 
 
2007 2.8% (n=1) lost in the follow up 
English et al. 
2012[76] 
Prospective 289 decisions, 
210 patients 
April-July 
2007 
Breast 5% (n=20 decisions)  65% (n=13) patient choice 
20% (n=4) doctor changed treatment 
15% (n=3) new clinical information become 
available 
Rajan et al. 
2013[79] 
Retrospective 3230 
decisions, 705 
patients  
Breast  4.5% (n=146 
decisions) 
41.8% (n=61) patient choice  
37% (n=54) new information become available 
after the MDT meeting 
17.8% (n=26) unjustifiable( no apparent reason)  
3.4% (n=5) MDT error 
Petty et al. 
2002[85]  
Prospective  153 decisions Various  12% (n=18 decisions)  Reasons for non-implementation were not 
analysed. 
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2.4.4 Time to implement treatment 
Patients with implemented MDT decisions had a significantly shorter time to the 
commencement of their final treatment plan compared to those for whom the MDT decision 
was changed, as demonstrated in the table below (Table 3). 
 
Table 3: Time delay in implemented versus non-implemented decisions. 
Study Study sample Time to treatment 
(implemented decisions) 
Time to treatment 
(changed decisions) 
P value 
Goolam-Hossen et al. 
[74] 
363 decisions Median 24 days IQR 12-
33 
35 days IQR 17-77.5 
(i.e. 11 days delay) 
0.009 
Caudron et al. [81] 309 decisions Mean 33.9 days SD 41.2 
n=272 
No data No data 
Osarogiagbon et al. 
[84] 
454 Median 14 days 
mean=29.9; SD=65.4 
Median 25 days Mean 
43.9 SD=54.9 (i.e. 14 
days delay) 
0.002 
Leo et al.[82] 97 Median 20 days No data No data 
 
2.5 Discussion 
2.5.1 Summary of results 
To the best of my knowledge, this is the first systematic review to investigate the 
implementation of MDT decisions and its impact on patient care. This review has found that 
the main barriers to implementing the MDT care plan include:  new information or decline in 
patient‟s health status and lack of information on patient‟s choice and co-morbidities. It was 
also found that, adhering to the MDT recommendations will result in a significantly shorter 
time to the receipt of the definitive treatment, compared to patients for whom their treatment 
plan changes for any of the reasons mentioned above.  
There is good evidence that using the MDT approach would shorten the time from diagnosis 
to treatment.[86, 87] This would have a great impact on the cancer targets and helps meeting 
those targets for better patient care and also to avoid fines that incur as a result of breaching 
these cancer targets. 
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My review showed that patients, who have their management plan changed for any of the 
reasons mentioned, will be treated more conservatively.  
 
An overall lack of a „holistic‟ approach ( the combination of the availability of appropriate 
investigation, patient factors and time factor) when discussing patients at the meeting has also 
been reported as a factor that affects reaching a decision at MDT meetings.[52] There is thus 
an overlap between the barriers to reaching a decision at the MDT meeting and the reasons 
for non-implementation of MDT decisions and that was ignoring patient related factors of co-
morbidities and psychosocial factors that may affect the implementation of such decisions. 
Lack of consideration of patient-related factors during MDT decision-making has also 
emerged in previous studies across tumour types in both self-report datasets and also in real-
time MDT observations.[26, 55, 75] 
 
2.5.2 Limitations 
The reviewed studies were of variable sample size and the majority were retrospective studies 
.[40, 77-81, 83, 84] The range and the number of tumour types covered by the review are also 
limited and heterogeneous. This limited number and heterogeneity of research represent a 
complex issue and provides a limited evidence base for MDT practice and a challenge for 
future research. Larger prospective studies would reduce the risk of studies being under 
powered and would help to minimise bias. Only three papers[74, 75, 83] analysed and 
compared the outcome of non-implemented decisions and only 2 papers[74, 84] explored the 
difference in time to definitive plan between the implemented and the non-implemented 
decisions. Therefore, the small sample size could limit the generalisability of the findings.  
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2.5.3 Conclusion 
This chapter summarised the available evidence on cancer MDT decision implementation and 
in particular, reasons that hinder the implementation of MDT decisions and its aftermath. 
As there has been no agreed way to evaluate the efficacy of MDT meeting,[17] results of this 
review could support the hypothesis that the „implementability‟ of a MDT decision could be a 
potential measure of MDT performance, alongside survival and the quality of decisions, and 
perhaps it could be included in the peer review process as a quality measure. This systematic 
review included a number of surgical specialties, but there were no studies in urology. In 
order to investigate MDT decision implementation in urology in depth, I conducted a 
retrospective study to explore concordance with MDT recommendations and factors that 
result in discordance in this specialty (Chapter 3).  
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3 Implementation of MDT meeting decisions in urology. A retrospective 
study 
 
3.1 Chapter overview  
In the previous chapter, I presented the available evidence in the literature on MDT decision 
implementation and I found that the discordance rate varies among specialties. I analysed the 
time delay from the MDT decision to the implementation of final decision, which showed 
less delay if the decision was concordant. There is ,however, no available literature on this in 
urology. The current chapter explores MDT decision implementation and reasons for 
discordance of MDT decision in this speciality.  
 
3.2 Aims  
The aims of this study are to retrospectively assess the urology MDTs in: 
 Ability to make decisions and the barriers preventing such decisions from being 
made. 
 Decision implementation and reasons for discordance. 
 Time delay in concordant versus discordant decisions. 
 
3.3 Methods  
Electronic records of patients discussed at Urology MDT meetings of a large London 
teaching hospital from March 2010 to April 2011 were studied. There was one MDT meeting 
per week in this hospital that was linked via video-conferencing to 3 other sites.  At each 
MDT meeting, all decisions were documented on the MDT proforma by the presenting 
person and also the meeting minutes were updated by the MDT coordinator. The MDT 
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proforma were scanned into the Electronic Patient Record system (EPR), which is the main 
hospital patient recording database that contains referral and clinic letters too.  
 
Patient lists and meeting minutes for all the included MDT meetings were obtained.  These 
were searched alongside the EPR in order to investigate team recommendations and decisions 
implemented into patient care.  
 
3.4 Results  
3.4.1 Demographics  
Over a one year period (March 2010 to April 2011), a total of 1059 cases were discussed in 
the MDT meeting. Out of 1059, 79.3% (n=840) were new diagnosed or suspected cancer 
cases. The majority 82.4 %( n=873) of the discussed cases were cancer cases, whereas 17.6% 
(n= 186) were benign. 84.2% (n=892) were males and 15.8% (n=167) were females. Median 
patient age was 68 years (range 19-91). Tumour sites were: Bladder cancer 23.3% (n=247); 
Kidney cancer 22.8% (n=241); Prostate cancer 47.3% (n=501); Testicular cancer 5.5% 
(n=58); Ureteric cancer 1.1% (n=12). 
 
3.4.2 Decision making at the MDT meeting 
In 108 of 1059 (10.2%) cases, decision was not reached by the MDT. Reasons for that are 
shown in the figure below (Figure 5). 
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Figure 5: Barriers to reaching decisions at the urology MDT meeting. 
 
 
 
3.4.3 Decision implementation following the MDT 
 
783 of the 1059 cases were studied for whether the decision had implemented or not and the 
time delay in receiving the recommended/ actual treatment. The remaining cases that were 
excluded from this analysis were cases that had treatment options of active surveillance, 
palliative therapy, symptomatic control and follow ups due to the difficulty in determining 
the exact implementation time.  
Overall, 89.4% (n=700) of actual patient treatments were concordant with the MDT decision 
and 10.6% (n=83) were discordant with the MDT decision. The breakdown of reasons for 
making the MDT decision discordant, are illustrated in Figure 6. 
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Figure 6: Reasons for non-implementation of MDT decision 
 
 
Main reasons for non-implementation of MDT decision were patient‟s choice and 
comorbidity. The third main reason for deviation from MDT decision was the treating 
surgeon‟s choice. The latter could be explained by the fact that the surgeon who knows the 
patient well was not present at the MDT meeting when the case was discussed and patient 
factors were not considered appropriately for example- this was also reported in Chapter 4. 
Table 4 shows a summary of the results tabulated by cancer type.  
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Table 4: Summary of the findings per cancer type 
 
Tumour 
type 
Age 
median 
(range) 
Gender 
F:M    
n. 
New: 
recurrence/                                                                                           
progressive 
n. 
Benign/ 
inflammation 
n. 
No 
decision
n. 
Non-
implementation
n.(%) 
Bladder 69(25-91) 62:185 155:92 34 32 36 (14.6%) 
Kidney 62(28-89) 103:138 221:20 30 24 22 (9.1%) 
Prostate 70(49-89) n/a 440:61 108 40 17 (3.4%) 
Testis 31(19-72) n/a 52:6 14 10 6 (10.3%) 
Ureter 52(51-76) 2:10 8:4 2 2 2 (16.7%) 
 
 
3.4.4 Time delay in receiving treatment  
I calculated the time it took from the MDT decision to the actual delivery of the treatment in 
both patients who had a concordant and discordant treatment to that of the MDT. Patients 
with concordant decision received treatment in an average of 31.4 (SD=29.3) days compared 
to those who had their treatment changed who received their treatment in an average of 35.9 
days (SD=38.7). This was a statistically significant difference (P=<0.01, t-test), showing 
treatment delay for patients with discordant treatments. 
 
3.5 Discussion  
3.5.1 Summary of findings 
This study showed that the investigated Urology MDT could not reach a treatment decision in 
10.2% of the discussed cases and reasons for that were mainly because of the lack of 
investigation results available at the time of the MDT meeting. Although approximately 90% 
of the cases had a treatment plan reached by the MDT, 10.6% of these MDT decisions were 
not carried out in practice. Barriers to implementing the MDT decided care plan were mainly 
due to the ignored patient factors in the case discussion. These findings fall within the 
average range of other specialties in the rate of discordance that I discovered in my 
systematic review of the previous chapter (4-38%). This study also replicates the findings 
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from the systematic review for other cancer types in that it takes a significantly longer time 
for a patient with a discordant decision to receive treatment (11-14 days average delay). 
One of the reasons for changing the MDT decision was surgeon‟s choice; this raises the 
question of who could justifiably change the MDT decision! So far there is no documentation 
about the legal power of the MDT and whether the MDT decision is a shared responsibility of 
all the MDT members. In an international survey a question was asked of who would be 
responsible in a case of lawsuit, half of the respondents replied that it would be the treating 
doctor rather than the MDT members.[16] 
 
3.5.2 Limitations  
There were some limitations to the methodology of this study. The data was limited to one 
hospital in London which may affect the generalisability of the findings – however, the large 
sample size (n=1059) and the fact that the MDT meeting was linked via video-conferencing 
to 3 other sites (specialist MDT meeting) should give a representative sample of urology 
MDTs. This study was retrospective and the sub-sample that I used for the analysis of 
decision implementation and time delay in receiving the eventual treatment was small as I 
had to exclude some cases due to the difficulty in determining the exact time frame for 
receiving their eventual treatments which is a common limitation of retrospective studies. 
 
3.5.3  Conclusions  
This study has filled a gap that existed in the literature on decision implementation and time 
delay in receiving cancer treatment among urology cancer patients.  
This was a retrospective study that involved examination of patient records. In the following 
chapter, I will triangulate the findings of my review and the present study with the views of 
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the cancer specialists who attend and run MDT meetings on the matter of decision 
implementation post-MDT meeting. 
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4 Factors that can impact on decision making and decision 
implementation following a cancer MDT meeting. A qualitative 
interview study 
 
4.1 Chapter overview 
Chapters 2 and 3 have showed that neither all the cases listed on the MDT discussion list get 
a treatment decision nor all MDT decisions do get implemented in practice. These results 
were obtained from reviewing the literature and hospital records of MDT meetings. In this 
chapter, I report the views of core MDT members of urology and Gastro Intestinal surgery in 
a qualitative exploratory study that explores in depth the issue of decision making and 
decision implementation in these 2 specialties. 
 
4.2 Aims  
In this study, I aimed to investigate the views of expert urology and gastro-intestinal cancer 
service providers in relation to the effectiveness of their MDTs in reaching a recommendation 
for each presented patient and subsequently implementing this recommendation into patient 
care. I focused on the barriers in implementing MDT decisions in practice and how these can 
be overcome.   
 
4.3 Methods: 
4.3.1 Design: 
I employed a qualitative, semi-structured interview-based approach to investigate key issues 
surrounding MDT decision-making and decision implementation in urological and gastro-
intestinal (GI) tumours. Qualitative techniques based on expert contributions are appropriate 
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when complex clinical issues are to be investigated and experts‟ views are sought regarding 
care processes.[88, 89] The outputs of such studies are subsequently used as a basis for large 
scale surveys, expert consensus development, or the development of interventions. Within my 
research group, we have used semi-structured interviews with surgeons in studies of surgical 
decision-making,[89] surgical performance,[90, 91] and recently urology MDT decision-
making.[26] 
 
4.3.2 Participants and procedure:  
I carried out semi-structured face-to-face interviews with a purposive sample of MDT 
members across urology and GI Surgery. Participants included Urologists, GI surgeons, 
Oncologists, Cancer nurses, Radiologists and Histopathologists. In qualitative studies such as 
this one, the goal in participant selection is that the participants can provide information on 
the topic of the interview in some depth. Participant numbers, as such, are of lesser 
importance, provided the themes that emerge from the interviews are recurring („thematic 
saturation‟ criterion;[92] this was achieved in the present study). A purposive sample of 
representative members of both GI and urology teams across 3 hospitals in London, UK, 
were interviewed to reflect views from a range of perspectives. The study hospitals were 
chosen based on convenience (to ensure we had access to participants) and they were 
representative of a range of hospitals providing cancer care services to GI and Urology cancer 
patients – including inner city and community institutions. Participation was voluntary, 
informed consent was obtained, and anonymity was ensured throughout the study.   
 
An interview protocol was developed (Appendix 3), focusing on MDT members‟ views on: 
decision-making and barriers to reaching a decision at the MDT meeting; implementation of 
MDT decisions and factors influencing implementation; strategies to improve MDT decision-
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making and decision implementation. Participants were also asked questions related to the 
venue and teleconferencing facilities of their MDT meetings, and demographic information. 
To ensure face and content validity, the protocol was based on findings of our review of the 
literature regarding effectiveness of MDTs and the process they use to review patients and 
make care recommendations[23, 56] and also of recent qualitative findings on the same 
topic.[26, 49] Each interview lasted 15-25 minutes and was audio-taped and transcribed 
verbatim (an example of the transcript is presented in Appendix 4). 
 
4.3.3 Data analysis: 
To ensure accuracy in representing the participants‟ views and minimisation of researcher 
bias, a standardised approach to interview analysis was taken. After a joint analysis of two 
interviews, a coding framework of emerged common themes was developed by two trained 
clinical researchers (myself: surgeon; Maria Ahmed: foundation academic trainee trained in 
qualitative methods) to analyse all the interviews independently in order to identify emergent 
themes as per standard qualitative research practice.[92] Disagreements were resolved 
through discussion. The analysis was reviewed by a psychologist with extensive experience 
in patient safety and qualitative research (Sevdalis) and emergent themes tabulated alongside 
verbatim quotes for illustration. 
 
4.4 Results: 
4.4.1 Participants: 
Twenty-two MDT members (Consultants, experienced nurses) participated in the study 
(Urologists=5, Uro-oncologists=3, Urology Nurses=3, Histopathologists=1, Radiologists=1, 
GI surgeons=4, GI Nurses=3 and GI Oncologists=2) across 3 different hospitals in the wider 
London (UK) region.  
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The themes that emerged from the interviews and illustrative verbatim quotations are 
summarised and presented in the sections that follow.  
 
4.4.2 Venue and facilities of the MDT:  
Most participants (Surgeons=7, Oncologists=5, Nurses=2) said that their MDT meeting is 
held in a dedicated room equipped with video-conferencing facilities. Although useful for 
teams calling into a cancer centre, videoconferencing can interfere with the meeting and 
impede teamwork and team decision-making. Table 5 presents disadvantages of video-
conferencing from the cohort‟s perspective. 
 
Table 5: Disadvantages of video-conferencing at a cancer multidisciplinary team 
meeting 
Problems associated with video-conferencing Representative quotes  
On-going technological problems with the 
equipment 
“It cuts out every hour, so the units have to be 
reconnected after an hour.  So you get a two minute 
break there, and a lot of the time, especially at the X 
site, it breaks down, so you can‟t see any radiological 
images” (Surgeon 1). 
 
Poor communication within the team 
“There‟s a lot of mumbling going on, there‟s a lot of 
static, sometimes it cuts out” (Surgeon 1). 
“It‟s less personal; and it‟s also difficult especially 
when more than one person wants to speak at the 
same time and there‟s a little bit of a lag.  So that‟s 
obviously not the same as face to face when you can 
take turns in speaking” (Surgeon 5).  
Direct negative impact on clinical decision-
making  
“If you can‟t get links then it may only be one 
urologist making the decision, it could delay 
treatment if it‟s more complex” (Nurse 2). 
Cause of conflict and frictions within the 
team  
“Communication in video conferencing is not ideal 
because it tends to cause divisions between the two 
groups on the different sides when there‟s a change 
in treatment decision. So video conferencing may 
lead to tribalism, and what tends to happen is 
humans who are in the same room as each other tend 
to stick together, and therefore it creates tension 
between the two groups” (Oncologist 3). 
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4.4.3 Decision-making at the MDT meeting:  
Participants reported that, in the majority of patients, a management plan was decided at the 
MDT meeting (median response to the question “how often are you able to reach a 
management plan after case discussion”: 92% range 80-99%). Factors affecting negatively 
on the team‟s decision-making are summarised in Table 6 and discussed in detail below.  
 
Table 6: Factors influencing cancer multidisciplinary team decision-making 
 
4.4.3.1 Inadequate information 
Participants reported that lack of necessary information about the patients at the meeting 
obstructs decision-making: “...Well, some relevant crucial bit of history which no one is able 
to give us and not been stated in the letter and we feel we can‟t make a decision without that 
information” (Surgeon 8). 
The majority of participants (n=16) reported that unavailability of investigation results 
hampered decision-making: “...you may be awaiting a scan or pathology results, which you 
don‟t have...” (Surgeon 4). 
Factor Surgeons  
(Urologists & 
general surgeons) 
(n = 8) 
Oncologists 
(Uro-oncologists &  
GI oncologists) 
(n = 6) 
Nurses 
(Urology and 
GI) 
(n = 6) 
Inadequate information     
History  
Co-morbidities  
8 
5 
4 
2 
3 
3 
Psychosocial factors 2 3 3 
Investigation results 8 4 5 
Patient‟s wishes 3 1 3 
MDT key member not present 7 3 4 
Time pressure  3 2 0 
Technological problems (mostly 
with video-conferencing 
equipment; see Table 1) 
2 1 4 
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The patient‟s co-morbid state was reported as an elemental part of the information required 
for the MDT to make a decision: “...Just to give a quick example, if a patient has a treatable 
prostate cancer and he has no mobility? there is no way they can commute to the 
radiotherapy section five days a week for seven and a half weeks to have radiotherapy to 
their pelvis...” (Surgeon 2). 
In addition to availability, accuracy and „representativeness‟ of the information on the actual 
status of the patient also impact on decision-making “...I saw a man, he came to me as a 
second opinion a few weeks ago, and he ran up all the stairs here...  He‟d got a letter from 
the first oncologist saying, „I am very sorry, you are 76, we do not treat anyone over 75... You 
can‟t have radiotherapy.‟  ...And he went sailing every weekend, he went rock climbing - he 
was the fittest 76 year old ever...” (Oncologist 2). 
Concern was expressed as to whether the MDT could ever evolve to consider patient 
management to wholly take account of patients‟ wishes: “...It‟s key that the patient‟s wishes, 
their performance status, their abilities and their social status is taken into account when 
making decisions.  And you can‟t do that with a MDT, it‟s not a simple issue...” (Surgeon 3). 
 
4.4.3.2 Non-attendance of key team-members 
Treatment decisions are formulated by a team, thus the presence of the core team-members is 
necessary. A first consequence of a core member‟s absence is that the decision may be 
delayed to the detriment of the patient: “Sometimes the consultant who‟s in charge of that 
patient hasn‟t attended the meeting and therefore they need to wait until the next meeting and 
he‟s there to allow a decent discussion” (Surgeon 5). 
Furthermore, making a decision when a key team-member is absent may lead to an 
inappropriate treatment plan: I was away at a MDT meeting a few weeks ago.  The MDT 
recommended not to treat a person with salvage therapy for recurrent prostate cancer.  They 
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hadn‟t seen the patient.  The patient was 81 but he was a very fit guy, he was insistent he 
wanted treatment and that didn‟t come up at the MDT, so again, that patient opinion was 
missing and the co-morbidity was missing at the MDT and I actually overruled it......” 
(Surgeon 1). 
 
4.4.3.3 Time pressure  
Respondents reported that they spend 1-2 hours every week at the MDT meeting. Most of the 
respondents said that the assigned time for the meeting is not enough to discuss all the 
patients unless „you rush through the meeting‟. Patients not reviewed at that meeting would 
be deferred to next week‟s meeting – causing delay to patient care: “Too long but not long 
enough! People who are not discussed, they usually get bounced onto the following week‟s 
meeting” (Nurse 1). 
The impact of deferring patients was considered to affect both patients and the MDT meeting:  
“the impact of that is that things will be delayed for a week or so, and it can roll over 
because when you postpone five patients you‟ll be adding it to an already overbooked MDT 
list, so that would lead to another postponement, so it rolls over” (Surgeon 2). 
 
4.4.4 Implementation of MDT decisions: 
Participants reported that the majority of the decisions made by the MDT meeting get 
implemented (median response to the question “how often does the management plan you 
agree during the MDT get implemented”: 95%, range 70%-100%). The main reasons that 
impede implementation of MDT decisions were patient factors – including (i) lack of 
consideration of patient‟s co-morbidities, (ii) patient‟s choice, and (iii) disease progression 
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(i) Non-consideration of patient factors by the MDT:  
There was a consensus among the participants that taking into account patient-related factors 
is crucial to reach a correct decision and not doing so may lead to an inappropriate decision 
or the patient may refuse it and thus discordance between the MDT decision and the 
administered therapy may occur: “...the patient might look better on paper but actually 
physically the patient isn‟t fit or doesn‟t want anything done, so I think hopefully the 
consultant should know that” (Nurse 2). 
 
(ii) Patient‟s choice: 
Knowledge and consideration of a patient‟s preferences is another key factor that facilitates 
implementation of a team‟s decision: “If we knew what the patient‟s opinion was, I think it 
would save time actually and we wouldn‟t necessarily have to go back and have another 
discussion...” (Surgeon 1).  
 
(iii) Disease progression:   
 
Disease progression was mentioned as a clinical factor that can overturn the MDT decision: 
“Sometimes in the intervening period, something has changed, they‟ve become unwell, or 
sometimes if there‟s a delay in treatment their clinical stage progresses and it becomes no 
longer a relevant decision” (Surgeon 5).  
 
4.4.5 Strategies to improve decision-making and decision implementation:  
A number of strategies were suggested by the participants to improve the effectiveness of 
MDT decision-making and implementation – including better case preparation, effective 
team leadership, and involvement of an anaesthetist in the MDT (to immediately discuss 
whether a patient is fit for surgery if this is an option open for consideration, rather than 
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assess this post-meeting). More controversial views included inclusion of patients in MDTs 
and not discussing all patients (as is currently mandated in the UK). These are presented in 
detail in Table 7. 
Table 7: Strategies to improve multidisciplinary team decision making and 
implementation 
 
Proposed strategies for 
improvement  
Representative quotes 
More preparation for the 
case presentation (e.g. 
using a proforma) 
“We used to have one that the information was actually put on to that 
and it was projected onto a screen.......it actually worked quite well”, 
Oncologist 2. 
 
“We don‟t have all the information(for referrals), and we don‟t out of 
courtesy go back and say, “We are not discussing this patient till you 
give us all the information, But maybe we should start doing that 
because otherwise they are just getting away with sloppy standards”, 
Surgeon 8. 
Involving the patient in 
the MDT discussion 
 For 
 
 Against  
 
“In my opinion the best decision making will be done when there is a 
formal meeting involving the clinicians and the patient, the clinicians 
will decide immediately while the patient is there”, Surgeon 2. 
 
“This is where I think, probably, we need to be very careful about what 
we are going to make the MDT into. That will never work”, Surgeon 3.  
 
“No, I don‟t think – that‟s going to be counter-productive”, Oncologist 
3. 
“This is a highly technical discussion involving a whole bunch of 
experts and I don‟t think that is the right format for the patient to be 
present at”, Surgeon 8. 
"I think it‟s just not practical.  I think yes, they should be involved in a 
sense so that they know that a decision is being taken but  to have the 
patient in the room, it would just be a disaster”, Oncologist 4. 
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Effective leadership and 
chairing of meetings  
“Sometimes I feel like there should be one main person leading it 
because it sometimes becomes a bit of a free-for-all and there is a lot 
of over-talk and you cannot hear what‟s going on “, Nurse 5. 
“I think at the end of each patient there should be a period where we 
say “Okay, the decision is…” and someone clarifies exactly what the 
decision is and makes sure that everyone agrees with it, because 
sometimes a number of things are thrown forward but no one‟s 
actually said “Actually the decision is this.””, Surgeon 5. 
Refining the criteria for 
patient discussion at 
MDT 
“I can tell you what way we‟re going, we‟re going to separate MDTs 
(tumour specific MDTs).  I think that will help”, Surgeon 3. 
“...I don‟t think every patient needs to be discussed, and one of the 
problems we faced, the challenge, is the issue of watering down the 
MDT, protocol, protocol, protocol, we end up talking about them all 
and you end up on the three difficult cases that people have lost 
interest by then and sometimes you can miss...”, Oncologist 3. 
Involving the anaesthetist 
in the MDT process 
“.....the surgery may be cancelled and therefore the decision is not 
implemented/changed/delayed because the anaesthetist is deciding that 
more investigation is required. So an anaesthetist at the time of the 
MDT that would be a good idea as well”, Surgeon 7. 
 
4.5 Discussion 
4.5.1 Summary of findings 
This study explored experienced MDT members‟ views of the efficacy of their team 
decision-making and implementation – it specifically identified problems and also solutions 
to current barriers in achieving decisions that are appropriate and also get implemented as 
intended into patient care. The study showed that a management plan is not always 
formulated for all cancer patients that are reviewed at the MDT meeting. Furthermore, not all 
the MDT decisions get adhered to in practice. Participants estimated that around 91% of the 
cancer patients get a decision plan at the MDT meeting. Of those, only 90% get implemented 
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– these figures are close to the range of non-implementation that I found reported in the 
literature (4-15%)[75, 78, 80, 82] and hence corroborate and extend previous findings using 
an expert-elicitation methodology (qualitative interviews). 
 
Key reasons for not reaching a decision plan at the time of the MDT meeting were:  lacking a 
„holistic‟ approach when discussing patients at the meeting and absence of the treating 
clinician or a key member(s). Importantly, there was an overlap between the barriers to 
reaching a decision at the MDT meeting and the reasons for non-implementation of MDT 
decisions: that was ignoring patient related factors of co-morbidities and psychosocial factors 
(in addition to disease-related factors) that may affect the implementation of such decisions. 
This is an important finding, as it suggests that if these issues are addressed, improvement 
will be obtained both in reaching a decision on first case presentation and also in 
implementing that decision in patient care. Lack of consideration of patient-related factors 
during MDT decision-making has also emerged in previous studies across tumour types in 
both self-report datasets [26] and also in real-time MDT observations.[42, 55] 
 
This study also identified strategies to improve decision-making and implementation. 
Amongst these was the usage of a proforma in preparing cases for MDT discussion. To this 
effect, an evidence-based checklist tool was recently developed for use in MDTs by our 
group – the MDT-QuIC.[93] Strong and effective chairing and leadership of the team 
meeting and including an anaesthetist to ensure patient fitness for surgery were also 
mentioned. More contentious strategies also emerged. The first was the suggestion to refine 
the inclusion criteria for MDT discussion (so that the team has more time to thoroughly 
discuss patients), either by splitting the MDT meeting into smaller meetings, or by excluding 
from review some patients that fall under clear protocols/guidelines. The former suggestion 
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may pose some logistical difficulties – as it will require further meetings to be fitted into 
already busy clinical schedules, and hence may require amendments to job planning for 
surgeons and other cancer professionals.[94] The latter suggestion is outside current 
mandatory practice in the UK – however, it is perhaps an avenue to reconsider in the future. 
A further contentious suggestion was inclusion of patients in the MDT. Some thought that it 
would enhance the decision-making, but others thought that this practice is counterproductive 
[95] and it would raise patient anxiety.[96, 97]  
 
4.5.2 Limitations  
Certain limitations apply to the study‟s findings. The participants were members of urology 
and GI surgery MDTs and so it is not possible to be certain how representative the sample is 
of MDT members of other specialties. Similarly, generalisability may also be hampered by 
the location of the study (London, UK) – although care was taken to sample participants from 
3 hospitals. The small sample size and indeed the self-reported nature of the data could 
further limit generalisability of the findings. This is a limitation of all qualitative studies – 
however, such studies are necessary if detailed understanding of experts‟ views is sought. 
Importantly, all possible steps were taken in the data analysis to ensure minimization of bias, 
participants were recruited from a large geographical area and also a key strength of the study 
is the representativeness of the professional groups in both tumour types within the study 
sample. In order to avoid recall bias within the study as much as possible, the interviews were 
audio-recorded and transcribed verbatim. Moreover, previous studies in the UK and other 
countries have arrived at similar conclusions using both self-report and also observational 
methods, thereby lending validity to these results. Further validation of the views expressed 
in this study should be sought via larger scale surveys and more objective methods of 
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assessing MDTs in real time, like standardised observational instruments, which are now 
available.[43] 
 
4.5.3 Conclusion  
I believe that these findings can be used as a basis for designing and implementing acceptable 
and thus implementable interventions based on our respondents‟ expert views. Recently 
published data suggest a cost of £87.41 ($141.95) per case discussion in a UK MDT[64] – 
which reinforces the point that MDT-driven care is expensive.[98] Non-implementation of a 
MDT decision is therefore not only a time/prognosis problem, but also a cost-related issue – 
as these patients have to be re-reviewed. This study provides an understanding of the factors 
that affect decision-making and implementation from the service providers‟ perspective and 
also outlines the strategies to tackle such barriers – some of which are more contentious than 
others (including more direct patient involvement in the MDT and also patient selection for 
MDT discussion).  
 
In this chapter, I have explored the views of the clinical core MDT members. In the following 
chapter, I will investigate the views of a non-clinical member group of the MDT, the MDT 
co-ordinators, in order to assess their views and needs in the process of the MDT. 
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5 The MDT meeting from the coordinators‟ perspective  
 
5.1 Chapter overview  
In chapter 4, I explored qualitatively the views of 22 MDT members (Urologists, GI 
surgeons, Oncologists, Cancer nurses, Radiologists and Histopathologists) on their thoughts 
about the functionality and effectiveness of their MDT meetings. In this chapter, I analyse the 
responses of a national sample of the MDT coordinators to a survey in order to investigate the 
views of the non-clinical members of the MDT on the process of MDT meeting. 
 
MDT coordinators are core members of the MDT meeting.[99] The role of the MDT 
Coordinator is relatively new, and as such it is evolving. The pivotal contribution of the MDT 
coordinator to the effectiveness of an MDT has been acknowledged in a survey of 2000 MDT 
members in the UK.[32, 99-101] Their duties involve identifying patients for discussion prior 
to the MDT meeting, organising meetings, facilitating and coordinating the logistics for the 
MDT meeting. They ensure that an appropriate number of patients are discussed at the 
meeting. MDT coordinators help in the introduction and changes to the proformas used to 
ensure all patients are discussed, treated appropriately and outcomes are recorded and 
reviewed. Furthermore, they play a crucial role in bridging the communication gap between 
the service provider and the patients to enhance the patient-centred care.[102]  
 
5.2 Aims  
The aim of the survey reported here is to assess the views of MDT coordinators on their roles 
within the MDT. More specifically, the objective was to explore the views of the MDT 
coordinators on: 
1. The MDT decision making process and barriers to reaching a treatment decision. 
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2. Their role as coordinators and its requirements, with a focus on educational and 
training needs. 
 
5.3 Methods 
 
5.3.1 Study design  
This was a prospective electronic survey study. The questions were structured for the purpose 
of the survey which was three-fold: first, to explore the prevalence of the role of the MDT 
coordinator in  cancer MDTs nationally (currently the UK Intercollegiate recommendations 
does not mandate that every MDT should have an MDT coordinator[101]).  Secondly, to 
explore their views, as core members, on the MDT efficacy and the process of decision 
making and ,thirdly, to explore their duties and requirements with focusing on training for the 
MDT coordinators. The development and implementation of training was given a priority by 
the Intercollegiate Cancer Committee ICC.[101] 
 
The study was carried out in accordance with the declaration of Helsinki. This study was 
reviewed by the National Ethics Research Services NRES and deemed that ethics approval 
was not necessary (Email from NRES provided in appendix 5). 
 
5.3.2 Survey instrument  
An online survey was administered electronically via freely available software 
(http://www.surveymonkey.com). The survey comprised a total of 47 questions (the survey is 
provided in Appendix 6). Most of the questions were multiple choice questions; others 
required a yes or no answer. Six demographic questions assessed the respondents‟ 
background ( professional group, gender, job title, age, work place and hospital type);  Nine 
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questions were about the MDT ( e.g. venue, frequency and the MDT specialty(s) they 
coordinated); seven questions assessed the coordinators‟ views on the discussion procedure 
of the MDT meeting (e.g. the frequency of the pathological or radiological images being 
displayed, if patients‟ views, psychosocial or co-morbidities have been considered, and who 
contributes to decision making); five questions assessed respondents‟ views on decision 
making processes and barriers thereof; eleven questions covered administering and 
coordinating of MDTs (e.g. the ease of preparing for the MDT, data recording  and decision 
communication); five questions explored the coordinators views on MDT chairing and 
leadership( e.g. who chairs the MDT and whether the chair rotate or could/should rotate); and 
four questions assessed training for MDT coordinators ( e.g. have you had a training for your 
role? And in which areas do you think you need training?).  
 
5.3.3 Participants  
A purposive sampling technique was used to target the population of interest. The National 
MDT Coordinators Forum is the national professional organisation for MDT coordinators in 
the UK. A link to the survey was sent to MDT coordinators, administrators and managers of 
all cancer types across the UK via the National MDT Coordinators Forum. Survey recipients 
were asked to circulate the survey to other relevant MDT coordinators (snowballing sampling 
technique). Responses were anonymised, but a unique identifier was awarded to each 
respondent to enable comparison between respondents‟ answers. 
 
5.3.4 Data Analysis  
All statistical analyses were performed using SPSS version 19.0 (SPSS Inc., Chicago, IL, 
USA). Descriptive statistics (means and standard deviations) were calculated for all survey 
items. Pearson Chi-Square was used to test whether there was an association between having 
70 
 
 
undertaken training and stating that further training was required. Pearson Chi-square was 
also used to test for any association between role (MDT coordinators and their equivalents) 
and training received/further required. Statistical significance was taken at the 0.05 level. 
“Coordinator equivalents” in this study is referring to the personnel who work as MDT 
coordinators, but are not so by job title. 
 
5.4 Results: 
5.4.1 Participants‟ demographics 
In total, there were 265 respondents to the survey. The majority of the responders were 
females (86%). The median age among the respondents was 40-49 years. 44.2 %( n=117) 
considered their hospitals to be a teaching hospital, 9.8 %( n=26) from tertiary centres, 42.6 
%( n=113) were from District General Hospitals (i.e., community hospitals across the UK). 
Table 8 shows the percentage of respondents who coordinate each tumour type (with some 
respondents coordinating more than one). 
 
Table 8: Percentage of respondents who coordinate each tumour type (more than one 
response permitted) 
Area/Tumour type % Area/Tumour 
type 
% 
Colorectal  17 Haematology  9 
Upper Gastro-Intestinal 14 Skin  8 
Gynaecology 14 Central Nervous 
System/Brain 
4 
Urology 13 Children 2 
Lung  12 Endocrine 3 
Breast 11 Palliative care 2 
Head & Neck/Ear, Nose & Throat (ENT) 10   
 
71 
 
 
5.4.2 Job analysis 
Regarding professional group, 82.6% (n=219) reported themselves as MDT Coordinators 
(Group 1), the remaining (Group 2) were: 7.5% (n=20) administrators, 3.4% (n=9) cancer 
managers, 3.4% (n=8) nurses and 3% (n=8) were doctors (Grouping the respondents into 
Group 1 and 2 was to see if other health professionals‟ views are similar to those who 
coordinate MDT meeting as their primary job). 52 %( n=138) of respondents had the title of 
MDT coordinator, whilst the remaining 48 %( n=127) had additional or alternative titles, 
which may explain why 37.7% (35.8% in Group 1 and 46.7% in group 2) felt that the job 
plan does not reflect their actual duties. Respondents had most commonly entered the 
position of MDT coordinator from other administrative positions in the NHS 41.5% (n=110), 
but 11.7% (n=31) had come from non-NHS jobs. 51.3% (n=136) of the participants worked 
in satellite hospitals, 41.1 %( n=109) were from specialist cancer centres, and 8.7% (n=23) 
worked in both. Regarding MDT work, 21.5% (n=57) attended an MDT meeting more than 
once a week, 31.7% (n=84) about once a week while 4.2% (n=11) of the respondents 
attended once every 2 weeks. 
 
5.4.3 Respondents‟ views on MDT case discussions  
Respondents felt that medical members of the MDT (e.g., surgeons (41.5%), oncologists 
(32.8%)) always contribute to case discussions, whilst nurses nearly always (18%) contribute, 
and MDT Coordinators sometimes contribute (15.8%). Regarding the weight that the 
opinions of different MDT members have in deciding treatment decisions, it was reported 
that surgeons‟ opinions were deemed to always carry weight (23.4%), those of oncologists 
nearly always (13.2%), radiologists usually (11.3%), pathologists and nurses sometimes 
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(12.1% and 17.7% respectively), and MDT coordinators never (37.7%). Nearly half of the 
respondents felt that disagreements do not happen very often (Figure 7). 
 
Figure 7: Respondents views on disagreement with MDT plan 
 
5.4.4 MDT chairing and leadership* 
For the position of chair of the MDT, 66.9% (n=105) of respondents said the MDT meetings 
were chaired by surgeons, 33.8% (n=53) physicians, 19.7% (n=31) oncologists, 5.7% (n=9) 
radiologists, 3.8% (n=6) pathologists, 1.3% (n=2) MDT coordinators and 0.6% (n=1) cancer 
manager. Under a quarter 24% (n=39) stated that the chair rotated between members, though 
68% (n=110) thought that the position of chair should rotate. When respondents were asked 
about how the meeting goes when the usual chair is away, 3% (n=5) said better, 84% (n=133) 
the same and 13% (n=21) said worse. 
*Some respondents selected more than one choice for MDT chairing hence the total number does not add up to 
100% 
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5.4.5 Barriers to MDT decision making 
The MDT coordinators reported that decisions for cancer patients are not always formulated 
in the first presentation at the MDT meeting. 46% of the respondents thought that nearly 
always a clear decision is made at the first presentation while 29% thought that there is 
usually a plan compared to 13% who said there is always a plan. There was no difference 
between the satellite hospital and the specialist centre in the frequency of reaching a clear 
plan in the first presentation of a case at the MDT. Respondents felt that when it was not 
possible to make decisions on cases at the first presentation, barriers were most commonly 
due to the lack of radiological or pathological information, or non-attendance of key 
personnel (Figure 8). 
 
Figure 8: Barriers to reaching a decision in the MDT meeting 
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5.4.6 Administering and coordinating cancer MDTs 
 The survey results suggest that coordination and administration of the local MDT is easier 
than that of the specialist, or that of the supra-specialist MDTs (Figure 9). Different types of 
patient tracking software were reported available (patient tracking software is a computer 
system that can be used to enter patient details including background history and 
investigation results. It also allows keeping patient records and MDT discussions and 
decisions, in this case, efficiently i.e. replacing the manual transcription and paperwork). 
Over 90% of respondents had patient tracking software at a local level, with this falling to 
60% at specialist level and to less than 40% at supra specialist level. 
Just under half of respondents were able to input data from MDT meetings in real time during 
the meetings. Fewer than 30% transpose data into national databases. Regarding 
communication of the outcome of the MDT meeting, email was the most frequent means of 
communication to administrators and clinicians. Respondents tended to communicate to GPs 
by dictated letters. Approximately three quarters of respondents are able to send out decision 
or minutes from MDT meetings on the same day as the meeting, and over 90% within 48 
hours, at a local level. 
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Figure 9: Ease of MDT meeting coordination and administration 
 
5.4.7 Training  
The majority of respondents had undergone some kind of induction course and received 
training in Data systems and IT, data protection and sharing. The figure below outlines the 
areas in which training was undertaken and others that training needs are unmet and further 
training deemed required by the MDT coordinators (Figure 10). 
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Figure 10: Training undertaken versus further training required for MDT coordinators 
 
There was no significant difference between group 1 (MDT coordinators) and group 2 (their 
equivalents) in receiving formal teaching in the areas of data system and IT (2 = 0.917, 
P=0.33), General Oncology (2 = 1.958, P= 0.16), Anatomy and physiology (2 = 2.286, 
P=0.13), Medical Terminology (2 = 2.719, P= 0.09), videoconferencing ((2 = 1.432, 
P=0.231), brief induction course (2 = 0.962, P=0.327), patient pathways (2 = 1.136, 
P=0.287), taking complex minutes (2 = 1.826, P=0.177) and data protection (2 =1.032, 
P=0.310). However, there was a significant association between the groups and training in 
receiving formal training in the following areas: specialist Oncology (2 = 6.120, P=0.013), 
coding (2 = 10.064, P=0.02), leadership (2 = 27.0, P=<0.001), communication skills (2 = 
16.824, P<0.001), audit and research (2 = 25.18, P<0.001), peer review (2 = 12.673, 
P<0.001) and negotiation skills (2 = 19.097, P<0.001).  Interestingly, wherever there was a 
significant difference, the coordinators reported having received less training than group 2. 
Finally, there was no significant difference between the 2 groups‟ views in the requirement 
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for further training, which suggests that the role of MDT coordinator necessitates education 
and training regardless of the professional title of the person designated for this job. 
 
5.5 Discussion  
5.5.1 Summary of findings 
To my knowledge, this is only the second study of its kind in the UK, following a 2006 
survey of the colorectal MDT coordinators.[103] Nearly half of the MDT coordinators felt 
that their job plan does not reflect what they actually do. MDT coordinators feel that they 
neither contribute to the MDT discussion nor their opinions carry weight in treatment 
decisions. Regarding leadership of MDT meetings, they thought that MDT meetings are 
mostly chaired by surgeons. MDT coordinators reported that there is not always a decision 
for each cancer case discussed at the MDT meeting and reasons for such are variable but lack 
of investigation results and non-attendance of a key member were the commonest. Finally, 
respondents appear to have received some relevant training and have access to equipment and 
facilities appropriate for the job. A learning need analysis from a focus group study identified 
a need for an educational programme for MDT coordinators.[104] 
 
Comparing the results of this survey which was conducted in 2011 to the 2006 survey of the 
colorectal cancer MDT coordinators,[103] there is a marked improvement in the job related 
training received by the MDT coordinators and their equivalents. For example, compared to 
the 2006 survey, the percentage of MDT coordinators who had training has increased from 
22% to 57.7% in data systems and IT, from 17.8% to 31.7% in general oncology and from 
8.9% to 32.1% in anatomy/physiology. The role of the MDT coordinator is evolving and, as 
such, training and education should meet the needs of such developing role. 
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Importantly, although MDT coordinators appear to not have a direct role in clinical decision-
making, their work supports the decision-making of the clinical members of the MDT and, 
without it, decisions could not be made. These findings support our team‟s previous 
research,[105] as well as work carried out by others, including the National Cancer Action 
Team, and the ICCC of the Royal Colleges that recognises the role of the MDT coordinator, 
as well as the need to strengthen the position by improving resources and training available to 
MDT coordinators nationally.[103, 106, 107] This view has been reflected in the 
establishment of the National Team for Cancer MDT coordinators (formally known as the 
Taskforce), the MDT coordinators forum, and the Annual Conference, along with 
development of national job descriptions and training programmes.[101]  
 
5.5.2  Limitations  
The results of this study are subject to certain limitations. There is no available statistical data 
on the total number of the MDT coordinators; however the majority of the 1500 MDTs in the 
UK are supported by a coordinator or an equivalent. Data on the educational background of 
coordinators was not gathered and may therefore be a confounder with regards to the level of 
training already undertaken as participants may have trained elsewhere prior to their work as 
MDT coordinators. The method used to recruit the survey sample involved snowballing so it 
is not possible to calculate the response rate. This means it is not possible to estimate the 
representativeness of responses. Furthermore, although the survey software records a unique 
identifier for each respondent, it is impossible to verify that each response is from a separate 
individual, and therefore guarantee the integrity of the dataset. However, the sampling was 
successful in representing respondents across MDTs and different tumour types throughout 
the UK, and we have no reason to believe that respondents filed multiple surveys. 
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5.5.3 Conclusion 
In this chapter, I have referred to the important role of coordination in the process of the 
MDT meeting. To further investigate that, I conducted this survey to explore the MDT 
coordinators views on the MDT and what are the unaddressed needs and requirements around 
their duties. The study raises the issue of training and education for the MDT coordinators. 
The study has shown that there is an expressed need to train those key members of the MDT. 
Perhaps it is the time to seriously consider training or fill the gap in MDT coordinators‟ 
education and training in the skills required for them to carry out their role with maximum 
effectiveness, with the view of further enhancing cancer care. The MDT meeting should not 
be seen in isolation, but rather as a pivotal point in the patient care pathway, linking  
information about patients and their disease to the decision making process, and then to the 
on-going care of the patient thereafter. The role of the MDT coordinator is therefore central 
to the care of cancer patients, both locally, and also through the coordination and sharing of 
data on a wider level. 
 
It has become obvious from chapters 4 and 5 that the reasons behind some discordance of 
MDT decisions and care subsequently implemented within the cancer pathway reflect the 
decision making process during the meeting. Considering the factors that affect decision 
making in MDT meetings would lead to improvement in both decision making and hence 
implementation of these decisions. In the following chapter, I present the findings of a 
national survey in an attempt to address some of the challenges faced by MDTs and to gather 
suggestions from the core members regarding interventions to improve the MDT 
performance.  
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6 Strategies to improve the utility and efficiency of the urology MDT 
meeting. A survey study 
 
6.1 Chapter overview  
In chapters 4 and 5, I explored the views of MDT members on some of the challenges faced 
by the MDT. In this chapter I analyse the findings of a national survey where some of the 
shortcomings identified in the previous studies are presented to MDT members in order to 
gather their views and suggestions on how to improve the efficacy of the MDT meeting.  
 
Evidence is emerging of the benefits of multidisciplinary working in cancer care.[63] It is 
thought that time spent at the MDT meeting saves time for members later, but questions 
remain as to how this time is saved. There is evidence that MDT meetings are high pressured, 
rapid with high numbers of cases without adequate time to permit the often necessary in-
depth discussion.[43, 57, 108] Many cases will need repeated discussion at various points 
along the care pathway and, although there is no obligation to discuss cases of recurrent or 
relapsing disease, these are often complex and may benefit most from a multidisciplinary 
approach.[61] Whilst improving the quality of clinical decision-making is admirable, one 
potential critique of such quality improvement work is that there is no time to discuss every 
case in depth. Moreover, such in depth discussion may not be necessary or even desirable for 
all cases.  
 
6.2 Aims  
The specific objectives of this study were to assess the perceptions of MDT members 
regarding: 
 The usefulness of MDT meetings 
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 Whether MDT working saves time later, and if so, how 
 Strategies for improving the efficiency of MDT meetings, namely 
o Treating some cases by protocol, going through the MDT meeting as "chair's 
action" 
o Prioritising cases at the MDT meeting 
o Splitting the MDT meeting 
 
 
6.3 Methods  
6.3.1 Study design and materials   
This was a prospective cross-sectional study. An online survey using a freely available survey 
engine (www.surveymonkey.com) was constructed (Appendix 7). The survey comprised 
demographic questions. Three questions asked the respondents about the time they spend at 
MDT meetings and whether this time is beneficial. Three questions covered the respondents‟ 
views on whether all cancer patients should be discussed at the MDT meeting, while other 
questions explored respondents‟ views on the caseload burden and whether splitting the MDT 
into smaller meetings can optimise how the meeting is run. Some questions were answered 
on a 5-point Likert scale (1=strongly disagree, 3= neither agree nor disagree, 5=strongly 
agree), some were multiple choice, and others required free text responses. The study was 
locally approved as a service improvement project prior to data collection. 
 
6.3.2 Participants 
Two surveys were conducted on separate occasions using the same questionnaire. The first 
survey was sent to the attendees of the British Uro-oncology Group (BUG) annual meeting in 
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2011. Other participants were recruited via the North London Urology Group and North East 
London Cancer Network. The second survey was administered to the attendees of a national 
Royal Society of Medicine (RSM) meeting that was jointly organised by the Oncology 
Section of the RSM and BUG in 2012 („What's new – What's changing in prostate cancer?‟ 
meeting). The surveys were aimed at the three core MDT groups attending these meetings – 
i.e., Oncologists, Urologists and Clinical Nurse Specialists (CNSs). The survey link was 
emailed to the attendees of the events prior to the meetings. No reminders were administered. 
 
6.3.3 Data analyses 
Statistical analysis was conducted using SPSS version 19.0 (SPSS Inc., Chicago, IL). 
Descriptive analysis (mean, median, standard deviation and percentage as appropriate) was 
carried out on scale and on binary responses. Kruskal Wallis test (KWT) was used to 
determine significant differences between respondent groups in these questions. Free-text 
responses were analysed qualitatively: themes were extracted from respondents‟ surveys, 
which were collated depending on their frequency.  
 
6.4 Results 
6.4.1 Participants‟ demographic information  
In total, 173 participants completed the surveys. Overall response rate was 54% (320 email 
invitations were sent). Respondents included 77 Oncologists (44.5%), 30 Urologists (17.3%), 
54 CNSs (31.2%), and 12 other specialties (6.9%) (GP=3, Radiologists=2, Radiographer=3, 
Radiotherapist=3 and Scientist=1). One hundred and eleven respondents completed the 
survey fully (64.2%). 
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6.4.2 Time spent at the urology MDT meeting 
Oncologists spent more time at MDT meetings (median 3.0hrs/week, range 1-5hrs) compared 
to Urologists (median 2.0hrs/week, range 2-4hrs) and CNSs (median 2.0hrs/week, range 0-
5hrs). The likely reason behind this is that oncologists cover multiple specialties and attend 
different tumour type MDT meetings. 
 
The majority 68 %( n=75) of the respondents said that attending MDT meetings saves their 
time later. An open-ended question explored how attending MDTs achieves this. Emergent 
themes from the responses are shown in the below figure (Figure 11). Discussing and 
deciding on a care management plan for each patient in the presence of colleagues who ought 
to know about them was the top theme that emerged from this question. This was followed by 
the MDT‟s ability to help decide on the appropriate investigations, as well as being 
instrumental for patient consultations in the out-patient clinics. Other respondents felt that 
attending MDT meeting will save them time because all the relevant specialty experts are 
present in the meeting and referral to other relevant specialties is made easy, efficient and 
quick. Finally, improvement of patient records and administration were also potential benefits 
reported by some of the participants.  
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Figure 11: How does attending the MDT meeting save time later? 
 
Interestingly, I did not obtain significant differences between the 3 groups regarding their 
views of the usefulness of the MDT meeting. In response to whether the time spent at the 
MDT meeting is useful, CNSs thought that 68% of the time spent at MDT meeting is useful 
for their own patients while Urologists said 57% and Oncologists 54% of that time is useful 
for their own patients. Regarding whether the time spent at the MDT meeting is useful for 
one‟s colleagues‟ patients, Urologists were most likely to agree (62%), whereas CNSs and 
Oncologists scored lower on this question (57% and 55% for CNSs and oncologists, 
respectively). Finally, the respondents were overall split regarding whether the time spent at 
the MDT meeting saves time later, 56% of CNS agreed with this statement, followed by 56% 
of urologists and only 42% of the oncologist respondents. 
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6.4.3 Improving efficiency of the MDT meetings 
6.4.3.1 Do all cancer cases need to be discussed at the MDT meeting?  
Overall, there was no significant difference between nursing and medical staff in relation to 
this question (P=0.34, KWT=0.075). The majority of respondents agreed or strongly agreed 
that all their cancer patients are discussed at the MDT meeting (nursing staff n=18 (90%), 
medical staff n=54(74%)). 
 
Since it is currently mandatory to discuss all new cancer cases at the MDT meeting 
(including the non-complicated cases where decision making is straightforward), we explored 
the respondents‟ views on whether those cases that fulfil an agreed protocol should be 
excluded from extended discussion and treated accordingly to save time for more in-depth 
discussion of more complex cases. Respondents from different professional backgrounds had 
different views with regards to the above question. In relation to specialist MDT meetings, 
medical staff were in agreement about excluding from the MDT discussion those patients 
whose management falls under a certain pathway or guideline (n=47 (61.8%)). CNSs, 
however, did not agree or were equivocal in their response (n=10 (59%)). Similar pattern was 
observed in the responses regarding the local MDT meeting (Figure 12).  
 
To further explore what type of  cancer cases could be managed without going through a 
detailed MDT meeting discussion, 29% (n=33/115) of the respondents thought that the MDT 
Chair could streamline patients with superficial bladder cancer from the MDT discussion 
(Figure 13).                                         
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Figure 12: Agreement with the statement „Some urology cases that are currently 
discussed in full at the urology MDT meeting could be treated by previously agreed 
protocol, and be put through the MDT as "chair's action"‟ 
 
 
 
Figure 13: What tumour types could be managed without going through MDT meeting 
discussion? 
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6.4.3.2 Could case discussion at the urology MDT meeting be prioritised – and how?  
Amongst the three groups, Oncologists were more open to prioritising cases followed by 
Urologists and Nurses, respectively. Prioritisation by tumour type was the most popular 
option (n=78 (80%)) in all three groups, followed by prioritisation by case complexity (n=65 
(68%)). Prioritisation by team members‟ availability was the least popular choice (n=56 
(60%)).  
 
Splitting the MDT meeting into smaller meetings was not a popular idea in respondents‟ 
views. Splitting by complexity was the most unpopular n=16 (17%) followed by splitting by 
team members‟ availability n=16 (18%). Splitting by tumour type was the least unpopular 
n=40 (41%). The disadvantages to splitting the urology MDT meeting as reported in the 
respondents‟ free-text comments are shown in Figure 14. The majority of the MDT members 
felt that splitting the MDT meeting into smaller meetings is wasting more time than it saves 
and that most healthcare professionals would not have extra time to attend more meetings. 
They also said that this will result in the meeting losing its multidisciplinary approach.  
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Figure 14: Disadvantages of splitting the MDT meeting 
 
 
6.5 Discussion 
6.5.1 Summary of findings  
This study explored core urology MDT members‟ views on how the current MDT model 
functions from their perspective and how to improve their cancer services through optimising 
the MDT meeting. The findings suggest that attending the MDT meeting is a considerable 
part of the participants‟ clinical work load (Urologists and Nurses spend on average 120 
minutes per week in the MDT meeting, with Oncologists spending longer, presumably due to 
their membership of other, non-urology, MDTs). Overall, however, participants felts that 
discussing patients in the presence of all experts at the MDT meeting is beneficial to all 
members and can save them time of planning and formulating a management plan for treating 
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their patients. The results suggest that members favour prioritisation of cases on clinical 
grounds, which might give those at the start of meetings a favourable environment for 
discussion. However, splitting the MDT meeting into smaller meetings was deemed 
unpopular and reasons for this unfavourable opinion were mainly time constrains and 
unavailability of all MDT core members to attend all the sub-meetings, thus losing the team 
approach in managing cancer patients.   
 
The related issue of whether all cancer cases should be discussed at the MDT meeting is more 
complicated. As discussion of all newly diagnosed cancer patients via the MDT meeting is 
mandatory, all simple and complex cases are brought to the forum for expert and a consensus 
opinion. The survey respondents, however, felt that this may not be necessary. In order to 
decrease the caseload (so that more complex patients are discussed with less time pressure) a 
selective approach could be appropriate by excluding some patients from the MDT 
discussion. These cases could be decided upon based on a combination of treatment protocols 
and Chair‟s actions. Those who favoured this selective approach thought that non-muscle 
invasive bladder and localised prostate cancer patients could be excluded from the extended 
MDT discussion. It should be noted, however, that CNSs did not favour this approach (i.e., 
not discussing patients).  
 
6.5.2 Limitations 
The sample used in this study was small, consisting only of three professional groups. The 
study sample may not therefore be representative of MDT members in general. However, the 
oncologists who participated were recruited from a national forum, and surgeons and nurses 
from a regional cancer network, and as such represent those core MDT members who have 
contact with patients, from a range of locations throughout the UK. In addition, sampling 
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only included core MDT members and it is thus possible that there are views by other 
healthcare professionals involved in urology MDTs that are not captured here. Importantly, 
however, the study did capture views of urologists, oncologists and clinical nurse specialists 
– all of whom are the core members of the urology MDT and contribute most to the team 
decision making.[59] Finally, as in all surveys, the findings are based on participants‟ self-
reported views and there is a possibility that as participation was opt-in in nature; those who 
responded are more favourably disposed to engaging in MDT working. More objective 
methods should be used to further validate these findings – for example, to test how to best 
prioritise patients for MDT discussion as proposed here. Overall, further replication of these 
results with more team members across more tumour types will reinforce the generalisability 
of the findings.   
 
6.5.3 Conclusion 
This study shows that the idea of streamlining the MDT by using a combination of agreed 
treatment protocols and Chair‟s actions for straightforward cases so that more complex cases 
can be discussed in more depth at the meeting is potentially viable. The premise of such 
prioritisation would be that there is no loss of decision quality, but there is a gain in time 
available to discuss cases that would benefit from multiple specialist inputs (like, for 
example, advanced or recurrent disease). Both of these aspects can be evaluated prospectively 
in future studies. The current view that all cases are „discussed‟ may in fact be erroneous. 
Case discussion has recently been measured to average just 3mins per case, which in itself 
does not represent a thorough discussion[43, 59] Short discussions may certainly be entirely 
appropriate – as some patients may require discussion lasting only seconds and others may 
take up significantly longer.  
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So far, in the few previous chapters, I explored the views and thoughts of the MDT members 
on the functionality of the MDT meeting, as well as the strategies that can be undertaken to 
face the shortcomings of the current MDT meetings. These studies were self-reported studies 
of the core members of different MDT meetings. The following chapters will explore the 
MDT meeting from an observational point of view and will also involve the development of 
systematic observational tools to assess some important aspects of the MDT meeting.  
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7 Systematic observational assessment of the quality of decision making 
in cancer MDT meetings   
 
7.1 Chapter overview 
The main duty of the MDT is to weigh up (process) the available information (input) about a 
cancer patient in order to reach the best treatment option that can be put in practice in a 
timely manner (outcome). The previous chapters have shown that there are shortcomings to 
each stage of it – using review methods (chapter 2), retrospective analysis (chapter 3), and 
self-report from cancer specialists (chapters 4 to 6). In order to further evaluate decision 
making during the MDT meeting, I used an objective assessment tool to scientifically assess 
the performance of the MDT. This enables me to study the „input-process‟ part of the MDT 
in more depth. Further, I took the assessment a step forward by not only using it in real time 
MDT meetings, but also in evaluating how feasible it is to assess MDT meetings remotely via 
video-recorded MDT meetings. 
 
7.2 Aims   
1. To assess and evaluate the scientific quality of MDTs using an observational tool- 
The Metric for Observation of Decision making in MDT meetings (MDT MODe). 
2. To assess the feasibility/usability of the instrument in real time as well as video-
recorded MDT meetings. 
3. To derive construct validation evidence for MDT-MODe via prospectively 
associating MDT-MODe scores with the ability of MDT to make a treatment 
recommendation on first case presentations.  
 
93 
 
 
7.3  Methods  
7.3.1.1 Case sample 
In total, 683 case discussion were observed and scored using the MDT-MODe tool (see 
section 7.3.1.2 below for a full description of the instrument) – of those, 556 cases were 
scored in real time via assessors attending the MDT meeting and 127 cases were assessed via 
video-recorded MDT meetings. The live assessed cases were all urology tumours; the video 
assessed cases comprised a range of tumours, including upper- and lower-gastrointestinal 
tumours, head and neck tumours, urology tumours and skin tumours.     
 
7.3.1.2 Design and procedure 
7.3.1.2.1 The instrument:  
 
MDT MODe is an instrument that was developed by our research group to assess clinical 
decision-making in MDT meetings. This instrument assesses 2 key aspects of team decision-
making:  
1. The quality of clinical and psychosocial information available to the MDT at the time 
of case discussion 
2. The quality of teamworking during case discussion. 
 
7.3.1.2.2 Design  
 
 3-phase prospective observational study design was used – as follows:  
 
Phase 1:  
A surgeon assessor of registrar level (myself) was first familiarised with the MDT-MODe 
instrument by the instrument developers (Ben Lamb: surgeon; James Green: surgeon; Nick 
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Sevdalis: psychologist). The assessor subsequently started prospective observations of 
urology MDTs, with regular feedback and guidance provide by one of the tool developers 
(BL). Observations were carried out in 4 different hospitals within the London, UK, 
metropolitan area. 
 
 
Phase 2:  
A second surgeon of resident level (Waseem Akhter) was trained to use MDT-MODe by 
myself and BL. Subsequently, 2 surgeon assessors carried out simultaneous blinded 
observational assessment of MDTs in real time across the same 4 hospital sites as in Phase 1.  
Upon completion of this phase, and prior to the video-based observations, the assessors 
refined the instrument to allow more accurate assessment of the team‟s decision-making. The 
following 2 items were added to MDT-MODe: 
- “Patient seen by a team-member”: this item was driven by national cancer care policy 
in the UK, where presence of an Attending-level physician who has seen the patient 
prior to the patient being discussed at the MDT is a quality indicator. 
- “Assessor aware of the teams‟ decision”:  this item was added to allow assessment of 
the clarity of the decision to the member of the team in attendance. The rationale 
behind the item was that if a surgeon observer is not aware of the final decision for a 
patient, the same may apply to other team-members – with the potential of confusion 
and delays in care.  
The ethical approval (originally provided for the MDT-MODe study [42]) was amended and 
obtained a favourable opinion. The approval of the substantial amendment is provided in 
Appendix 8. 
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Phase 3:  
Upon completion of the in vivo observational assessments in MDTs, and the instrument 
refinement, the same 2 trained assessors used MDT-MODe to prospectively assess video-
recorded MDT meetings. These recordings were obtained from 4 different community 
hospitals across England. 
 
 
7.3.1.3 Outcome measures 
 
Primary outcome 1: Objective MDT decision-making  
Whether a treatment decision was reached for each case was objectively recorded by the 
MDT coordinator (the dedicated administrator to the MDT) in the meeting minutes. This 
information was collated by the coordinator and provided to the research team. This outcome 
was only feasible to collect in the in vivo assessed MDT meetings.   
 
Primary outcome 2: Quality of MDT teamworking    
This was assessed via direct in vivo or video-based observation by the surgeon assessors 
using MDT-MODe (Figure 15). MDT-MODe assesses (i) the quality of information 
presented at the MDT when a case is reviewed and (ii) the quality of teamworking, i.e. 
individual team-member‟s contribution to team decision-making. Both these elements have 
been shown to be important facets of teamworking at the MDT meeting.[56] They are 
assessed using a standardized „behavioural marker‟ system, which was originally based on 
the well-validated scoring system of the „OTAS‟ tool for operating theatre teams which our 
group has developed[109, 110]  MDT-MODe assessors use 1-5 scales to evaluate quality of 
information and quality of a specialists‟ contribution to the team decision-making, which are 
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anchored at 1 (poor information quality/teamwork), 3 (average information quality/ 
teamwork) and 5 (excellent information quality/ teamwork).   
 
The assessors used the tool to rate team decision-making for every patient discussed. To 
minimise the risk of observer bias, the assessors were kept blinded to each other's ratings 
throughout the data collection. Upon completion of the observations, data were collated for 
statistical analyses.  
 
Secondary outcome 1: Objective MDT decision-making  
Reasons for the inability of the team to reach a decision (of the in vivo assessed MDTs) were 
recorded and analysed.   
 
7.3.1.4 Data analyses 
All statistical analyses were performed using SPSS version 20.0. (SPSS Inc., Chicago, IL, 
USA). Mean and standard deviation were computed for all behavioural ratings. Regarding the 
quality of the observed MDTs, analysis of variance (ANOVA) was used to statistically 
evaluate the differences in the quality of information presented to the MDT across different 
types of clinical and psychosocial information and the quality of contribution of the different 
specialists to the case reviews between observed in vivo and video-recorded MDT meetings. 
Further, independent sample t-tests were used to compare quality of presented information 
and also quality of team-members‟ contributions between cases where the MDT was able to 
reach a management decisions and those where no decision was reached on first case 
presentation.  
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Regarding the scientific quality of the observational assessments, inter-observer agreement 
was assessed statistically using Intraclass Correlation Coefficients (ICCs), computed with 
95% confidence intervals (95% CIs).[111] A cut off score of 0.70 or higher is typically taken 
as adequate for this type of observational assessment.[112, 113] Further, assessors‟ 
calibration curves were computed for all individual elements of the behavioural assessments 
to statistically evaluate assessors‟ improvement and cross-assessor consistency in their 
assessments over time. The curves were computed using ICCs for every „block‟ of 20 
consecutively observed cases.  
 
For all analyses, significance was taken at p<0.05. 
 
Figure 15: MDT-MODe II 
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7.4 Results  
7.4.1 Observed MDTs: descriptive information  
556 cases were scored in vivo (urology tumours) and 127 cases were assessed via video-
recordings (upper- and lower-gastrointestinal, head and neck, urology and skin tumours) 
using MDT-MODe – 683 case discussions were scored in total. Detailed descriptive 
information of the observed MDTs is shown in Table 9. On average, MDT meetings were 
attended by 12 specialists each (range 8-15 specialists), discussed 29.5 cases each (range 9-54 
cases) within 83.0mins (range 43-118mins) – such that every case was reviewed within an 
average of 2:49 mm:ss.    
Table 9: Descriptive information of all observed multidisciplinary team meetings 
 Session No. of cases Specialty Duration (min.) Average time/case 
(min:sec) 
No. of members present 
Phase 1 1 55 Urology 100 01:49 15 
2 30 Urology 80 02:40 13 
3 51 Urology 99 01:56 14 
4 38 Urology 85 02:14 14 
5 41 Urology 90 02:12 15 
6 37 Urology 85 02:18 13 
7 9 Urology 50 05:00 8 
8 36 Urology 85 02:22 13 
9 33 Urology 80 02:25 14 
Subtotal 9 332  754   
Phase 2 1 36 Urology 88 02:27 15 
2 47 Urology 95 02:01 12 
3 29 Urology 80 02:46 13 
4 40 Urology 88 02:12 12 
5 35 Urology 85 02:26 15 
6 37 Urology 90 02:26 13 
Subtotal 6 224  526   
Phase 3 1 13 Colorectal 99 07:37 12 
2 12 Colorectal 64 05:20 9 
3 13 Skin 54 04:09 10 
4 32 Urology 118 03:41 8 
5 15 Lower GI 97 06:28 12 
6 17 Upper GI 80 04:42 9 
7 16 Head & Neck 78 04:53 10 
8 9 Head & Neck 43 04:47 10 
Subtotal 8 127  633   
      
Total 23 683  1913 2:49  
Mean/ session  29.5  83.2  12.1 
SD  13.7  17.2  2.3 
Range  9-54  43-118  8-15 
99 
 
 
Primary & secondary outcome 1: Objective MDT decision-making and barriers to reaching 
clinical decisions   
556 cases were assessed in vivo and in those cases the objective meeting outcome was 
recorded in the formal meeting clinical notes by the MDT coordinator. Analysis of these data 
revealed that the MDTs were able to reach a clinical decision on first case presentation for 
496 of the patients (89.2%, 95% CI 86.4-91.5%) – in other words, 60 patients (10.8%, 95% 
CI 8.5-13.6%) had to be re-reviewed at a later stage.    
Analysis of the cases where no decision could be reached is shown in Figure 16.  
Lack of information, including imaging and histology findings were the key reasons for 
MDTs‟ inability to make decisions, followed by time pressure and non-attendance of a key 
team member (oncologist).     
 
 
 
Figure 16: Barriers to decision making 
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7.4.2 Primary outcome 2: Quality of MDT teamworking 
 
Two aspects of MDT teamworking were assessed. Firstly, the quality of presented 
information and secondly the quality of specialists‟ contributions to the case review.  
Data on each category of assessment of MDT-MODe are presented in Table 10.  
Regarding categories of quality of information, case history information was scored highest 
(averaged assessors‟ mean=4.20, SD=1.20) and information about psychosocial factors and 
patient views were scored lowest (mean=1.37, SD=1.06 and mean=1.27, SD=0.96, 
respectively). Regarding each team-member‟s contribution to discussion, surgeons were 
scored highest (mean=3.95, SD=1.61) and cancer nurses lowest (mean=1.28, SD=0.92). 
 
I statistically compared the cases where the MDT was able to reach a decision with those 
where such decision could not be made (Table 10). When the team was able to make a 
recommendation the majority of MDT-MODe assessment categories were scored 
significantly higher (all Ps<0.001). The only exceptions were information on patient views 
(which did not differ between cases with/without a decision) and quality of MDT chair‟s 
contribution (which was better in the cases without a decision, P=0.02).  
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Table 10: The relationship between individual MDT-MODe components and decision 
making. 
 
 Observed 
behaviours   
Score 
Decision 
made 
(mean) 
SD Score 
Decision 
not made 
(mean) 
SD t test 
Information History 4.36 0.961 2.68 1.85 <0.001 
Radiology 3.43 1.91 1.63 1.40 <0.001 
H/pathology 2.88 1.43 1.70 1.27 <0.001 
Psychosocial 1.41 1.10 1.07 0.52 <0.001 
Comorbidities 2.06 1.64 1.22 0.89 <0.001 
Patient views 1.28 0.997 1.13 0.62 0.259 
Total mean 
score 
 2.57 0.59 1.57 0.70
1 
<0.001 
Contribution Chair 2.97 1.82 3.67 1.68 0.02 
Surgeon 4.17 1.46 2.17 1.75 <0.001 
Oncologist 2.42 1.70 1.35 1.01 <0.001 
CNS 1.31 0.96 1.00 0.00 0.014 
Radiologist 2.90 1.96 1.35 1.12 <0.001 
Pathologist 2.25 1.81 1.47 1.30 <0.001 
Total mean 
score 
 2.67 0.63 2.04 0.63 <0.001 
Grand total mean score 2.62 0.52 1.96 0.59 <0.001 
 
 
 
 
Regarding the difference between scoring in vivo and video-recorded observation, overall 
there was variability across all domains. Video-recorded MDT meetings scored higher 
however statistical significance was only observed in members‟ contribution scores (Table 
11). 
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Table 11: Variability between scoring between in vivo and video-recorded MDTs 
 
 In vivo observations 
Video-recorded 
observations 
ANOVA 
 
 
Mean 
score 
SD Mean score SD 
Information  History 4.18 1.21 4.370 0.91 0.098 
Radiology 3.23 1.94 3.46 1.81 0.219 
H/pathology 2.76 1.46 3.07 1.47 0.290 
Psychosocial 1.37 1.06 1.32 0.92 0.573 
Comorbidities 1.97 1.60 1.94 1.41 0.842 
Patient views 1.27 0.97 1.43 1.09 0.103 
       
Contribution Chair 3.02 1.82 3.22 1.64 0.252 
Surgeon 3.95 1.61 4.43 1.05 0.002 
Oncologist 2.31 1.68 3.72 1.56 <0.001 
CNS 1.28 0.92 2.08 1.52 <0.001 
Radiologist 2.74 1.94 2.08 1.52 <0.001 
Pathologist 2.16 1.78 3.21 1.84 <0.001 
                                                                
 
7.4.3 Inter-observer reliability analysis: learning curves and assessor consistency    
 
Inter-observer agreement was assessed via intra-class correlations (ICCs). Reliability was 
calculated and was achieved after 2-3 meetings that remained consistently >0.70.  
 
Assessor learning curves for each element of the assessment are shown in Figures 17 (in vivo 
scoring) and Figure 18 (video-based scoring). Adequate agreement between the 2 surgeon 
assessors, defined as ICC of 0.70 or higher, was typically reached within 40-60 observed 
cases (analysis „blocks‟ 2-3) and maintained thereafter- showing good consistency in 
assessment. Comparably good levels of agreement were found in both the in vivo and the 
video-based scoring.  
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Figure 17: Assessors‟ agreement in consecutive MDT evaluations carried out in vivo 
during team meetings 
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Figure 18: Assessors‟ agreement in consecutive MDT evaluations carried out via video 
recordings of team meetings 
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7.5 Discussion 
7.5.1 Summary of findings  
 
Consistent with the 3 objectives I sought to achieve, this study firstly shows that assessment 
of cancer MDT teams‟ performance by clinical assessors is feasible, both in vivo and also via 
video-recorded meetings. Secondly, the study demonstrates that surgeon observers can 
provide a very good level of scientific assessment both in vivo and via video, with 
consistently reliable scoring across hundreds of patients. Finally, the study provides evidence 
that the quality of the teamworking within the MDT meeting is linked to the team‟s ability to 
make clinical decisions: for all patients for whom the team had to defer the decision, the 
quality of information available to the team at the time and also the quality of the team-
members‟ contributions were significantly lower compared to the patients for whom 
decisions were made.  
 
The MDT-MODe instrument is a scientific assessment of the non-technical aspects of a MDT 
– including the quality of information available to the team and also the quality of their 
contributions to the case review. In the past, the tool has been used to evaluate urology MDTs 
in vivo – and it was found that typically biomedical information is better covered than 
psychosocial elements, comorbidities are often neglected in the review, and cancer nurses 
tend not to contribute very much to the case review, even when they have additional 
information.[43] This study replicates this pattern – the same 3 aspects of the case reviews 
were the least well covered in the meetings evaluated in this study (even at the MDT 
meetings where clinical decisions were reached). Further, I found here that the case reviews 
were largely driven by surgeons – other doctors contributed significantly less, and nurses 
came lowest.  
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Lack of information at the time of the meeting was linked to significantly worse case reviews 
– every single specialist‟s contribution was scored significantly lower in the cases where 
information was missing. Lack of imaging and histology results was a key problem – but also 
lack of time and lack of oncologic presence in the MDT meeting were also factors associated 
with inability to make a decision. The observed MDTs failed to reach a decision for just 
under 11% of the patients they reviewed – this finding is fairly representative of the existing 
evidence base as I found in my systematic review (chapter 2).  
 
7.5.2 Limitations  
 
This study has limitations. Although meaningful links were obtained between MDT-MODe 
and objective decision-making at the meeting, the tool may not be equally sensitive in the 
scoring of all specialists in the MDT meeting. Histopathologists might get underscored as not 
every patient will have histopathological information and sometimes this information will be 
provided in the case history presentation. Similarly, cancer nurses‟ low scores may be partly 
due to the fact that some cases are discussed at the meeting before the nurses have had the 
opportunity to see the patients – hence their contribution will likely be limited. Moreover, the 
tool does require initial training – this, however, is what has recently been recommended by a 
national expert consensus study of nontechnical assessment tool developers, who all agreed 
that team assessors should first be trained.[114] Importantly, for application purposes, the 
assessors did not lose their consistency over time, and the agreement between them was 
transferred from the in vivo scoring to the video-based scoring. Furthermore, assessors found 
that video recordings of MDTs could be improved. The recordings were made using a single 
static camera, which made some aspects of the assessment unclear (including assessing the 
availability of histopathological slides and radiological imaging). A Hawthorne effect could 
have biased the assessments – such that presence of the assessors in the in vivo scoring or of 
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the camera in the video scoring altered behaviour during the meeting. This is a limitation 
present in all observational studies. Importantly, this equally applies to all meetings and 
hence the differences we obtained between the cases where a decision was reached and those 
that failed to reach a decision are unlikely to be due to bias. Finally, we evaluate significantly 
more urology MDTs than other tumours – so more data from non-urologic tumours are 
required to increase generalisability.   
 
7.5.3 Conclusion: 
 
The present study provides further reliability and validation evidence for a robust instrument 
to capture nontechnical aspects of performance in cancer MDT meetings, MDT-MODe. I 
have shown that performance assessments are viable via in vivo and also video-based 
observation, and that surgeon assessors can learn to use the instrument and remain reliable 
over time. MDT-MODe enables cancer teams to be evaluated, or to evaluate themselves, and 
feedback to be provided on how best to improve their team processes.  
 
While attending MDT meetings, I noticed that the duration and smooth running of case 
discussions were fairly variable – even if patient related factors were excluded (as these tend 
to be most variable). I soon realised that these aspects of the meeting were linked to the 
rotating chairperson. Some MDT chairs had effective chairing skills to run the teams, others 
did not. Indeed, sometimes if they had not introduced themselves as the chairperson, I would 
not have been able to guess who was the chair of some of the meetings as an observer. This 
led to the question of what constitutes good chairing in MDT meetings. The specifications 
and duties of the MDT chairperson/leader have been mentioned in the Characteristics of an 
Effective MDT document [11] and is the focus of the following chapter. 
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8 Chairing and leadership in MDT meetings 
 
8.1 Chapter overview 
In this chapter, I have taken a step forward towards assessing the MDT chairperson‟s 
performance by developing a robust evidence based observational tool. I will present the 
steps involved in the development of the tool, content validation and reliability of the tool. I 
will also demonstrate the feasibility of using the tool in both real-time observations and 
video-recorded MDT meetings.                                                                                                                                                                                                                                                                                                                                                         
 
As I mentioned in the introduction, high quality leadership and chairing skills are vital for 
good performance in MDT meetings. MDT performance in the UK is subject to a quality 
assurance exercise by the annual cancer „peer review‟ programme which provides an annual 
mandatory mechanism for assessment of MDTs against set standards, even though 
performance of MDTs can still be variable.[19] The standards incorporate the process 
(structural and functional features) of MDTs such as team composition however there is 
currently no available framework for other aspects of a MDT‟s functioning such as decision 
making, decision implementation or the quality of chairing of the MDT meeting. In the UK, 
the Department of Health has set guidance for MDT working.[38] Some standards in regards 
to the MDT‟s leadership are among the many aspects of the MDT that have been included in 
this guidance – however, who should lead/chair, their characteristics, what are their non-
technical skills and whether they ought to undergo any training are not specified. Based on 
my own research, the importance of good leadership and chairing of the meeting has been an 
emergent theme among the strategies to improve MDT decision making and implementation 
(chapter 4). This study aims to address some of these questions.  
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8.2 Aims 
The aim of this study was to develop a robust and valid tool to evaluate the MDT chairperson 
in leading the meeting through systematic and relevant criteria defined as critical for a MDT 
chairperson to have. 
 
8.3 Methods 
 
8.3.1 Development and initial validation of the tool 
An observational tool was developed to assess the chairing and leadership skills of MDT 
chairperson.  The available literature was first reviewed to gather information about the 
characteristics of effective chairing. The most relevant document was The characteristics of 
an effective MDT,[11] which includes a section on the leadership and also mentions a set of 
skills that an MDT chair should have. 
 
The early stages of instrument development included the largest pool of potential items 
possible (14 items), which was later reduced to 12 elements, based on content review by 
experts.[115] This procedure is described in detail below.  
 
The initial review and content validation of the instrument was undertaken in 2 stages: 
 
Stage 1: The characteristics of an effective chairperson were reviewed by 10 senior MDT 
members who regularly chair their MDT meetings. The characteristics were refined and 
merged as per the recommendations from these experts - this led to a revised version of the 
tool to come to its current shape consisting of 12 characteristics by which the chairperson 
could be assessed.  
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Stage 2: The revised version of the tool was validated by conducting an online survey of a 
national sample of Urology MDT members. Attendees of the Prostate Cancer UK Summit 
2012 workshop in London were invited to take part in the survey. Participants were asked to 
rate individual chairing characteristics on a Likert scale (Extremely important =5, 
Important=4, Does not matter=3, Least important=2, Not applicable=1). The survey 
questionnaire can be found in Appendix 9. In this stage, a Content Validity Index (CVI) was 
calculated for each item.[116] A CVI represents the proportion of experts who rated the item 
4 or 5 on the 5-point scale for its relevance to MDT chairing and leadership.[117] Higher 
CVIs indicate higher inter-expert agreement that the item is an important criterion of the 
MDT chairperson. Although there is not a definitive CVI cut-off, 0.78 is taken as a minimum 
acceptable CVI.[118] 
 
8.3.2 Tool reliability  
Following tool content validation, a number of MDT chairpersons were assessed by myself 
and another surgeon of registrar level (Akhter). The 2 assessors were kept blinded to each 
other‟s ratings throughout the assessment process to minimise the risk of bias. Seven real-
time Urology MDT meetings (286 cases) and ten video-recorded MDTs (131 cases) of 
different specialties were observed. A score of 1-5 assessing the chairperson was given by the 
observers against each individual criterion listed in the tool – such that the minimum score on 
the scale was 12 (representing poor chairing and leadership skills) and the maximum score 
was 60 (representing very effective chairing and leadership skills during the meeting). Inter-
rater reliability in assessments was evaluated statistically by calculating Intraclass Correlation 
Coefficients (ICCs) as in chapter 7. ICCs of 0.70 or higher were deemed to indicate adequate 
inter-rater agreement for research purposes.[112, 113]  
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The first version and the final version of the MDT chaining and leadership tool is shown in 
figure 19 and 20. 
 
How would you rate the MDT Chair on the following scale? 
Chairing Criteria Rating 
1. Ensure the meeting runs to time           1             2             3             4             5 
2. Communication           1             2             3             4             5 
3. Allowing/encouraging all team members to 
contribute ( team working) 
          1             2             3             4             5 
4. Ability to summarise            1             2             3             4             5 
5. Time keeping (all patients discussed)           1             2             3             4             5 
6. Each patient discussed has a clear treatment 
plan 
          1             2             3             4             5 
7. Keeping meeting focused           1             2             3             4             5 
8. Facilitate discussion           1             2             3             4             5 
9. Conflict resolution            1             2             3             4             5 
10. Leadership           1             2             3             4             5 
11. Creating a good working atmosphere           1             2             3             4             5 
12. Constructive and fair to the team.           1             2             3             4             5 
13. Development of the MDT and its activities           1             2             3             4             5 
14. Team training needs are identified           1             2             3             4             5 
 
Figure 19: The first version of the chairing and leadership tool 
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Figure 20: The MDT chairing and leadership tool. 
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8.3.3 Cross validation: MDT functioning and chairing/leadership  
My research group have developed and validated a tool to assess the MDT meeting – this is 
the MDT-MODe instrument I used in chapter 7.[43] MDT MODe allows the observational 
assessment of both  (i) the quality of information presented at the MDT meeting when a case 
is reviewed and (ii) the quality of team working, i.e. individual team-member‟s contribution 
to team decision-making including the chairperson. I used the MDT-MODe (the chair 
contribution component) alongside the chairing tool during both real-time and video-recorded 
MDT meetings and the scores from both tools were correlated for cross validation. 
 
8.3.4 Analysis 
All scores for all the chairing elements were analysed via descriptive statistics. Content 
Validity Index for the components of the tool was calculated from the survey responses.  
Intraclass Correlation Coefficients (ICCs) were used to assess inter-rater agreement.[119, 
120] Cronbach‟s alpha was used to assess the internal consistency across the tool domains. 
Pearson‟s correlation was used for cross validation purposes. Statistical analysis was 
conducted using SPSS version 20.0 (SPSS Inc., Chicago, IL). 
 
 
 
8.4 Results  
 
8.4.1 Demographics: 
Overall, 144 core MDT members responded to the national online survey to validate the 
content of the tool (Surgeons n=47, Nurses n= 37, Oncologists n=34, Radiologists n=24, 
others n=2). The majority 68% (n=71) of the doctors were Consultants. The majority of 
respondents 70% (n=101) spend ≥ 2 hours per week attending MDT meetings. 48% (n=70) of 
the respondents worked in a specialist centre, 36 %( n=52) of them worked in a non-specialist 
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centre and the remaining 16% (n=23) worked in both. Only 16% (n=23) of the participants 
chaired their MDT meetings regularly. Majority of the survey participants 81.4 % (n=99) 
reported that surgeons are usually chairing their MDT meeting. Oncologists were the second 
most frequent specialists in chairing the MDT meeting 35.2% (n=51). 
 
8.4.2 Tool content validation and internal consistency: 
Based on expert views (phase 1), a few of the tool items were dropped or merged and the 
revised version of the MDT chairperson assessment tool was further content validated by the 
survey of experts. The tool was then tested for reliability. 
  
Respondents felt that ensuring that all cases have a clear treatment plan is the most 
important characteristic of the MDT chair and ensuring recruitment for clinical trials was the 
least important. 
 
The CVI for each scale item is the proportion of experts who rate the item as a 4 or 5 on a 5-
point scale.[117] CVIs are shown in table 12. Higher CVIs indicate higher inter-expert 
agreement. 
 
Further, in order to assess internal consistency of the tool, Cronbach‟s alpha was calculated 
and showed good consistency at 0.80. This means that the 12 elements of the instrument tend 
to be scored in the same direction – which suggest good consistency in the overall tool 
scoring.[121] 
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Table 12: Number of the respondents to the survey to validate the content of the 
chairing tool and computed Content Validity Indices (CVIs) 
Items  
Respondents 
who rated the 
items as 5 
(Extremely 
important) or 4 
(Important) (n) 
Total 
Responses 
(n) 
         
 
 
CVI 
Time management 114 116 0.98 
Communication 116 117 0.99 
Team working 116 116 1.00 
Ensure clear treatment plans 115 117 0.98 
Ability to summarize 110 117 0.94 
Case prioritization 95 115 0.83 
Keeping meeting focused 113 116 0.97 
Facilitate discussion 108 115 0.94 
Conflict management 103 114 0.90 
Leadership 103 115 0.90 
Creating good work environment 106 115 0.92 
Recruiting for clinical trials 89 112 0.80 
 
 
8.4.3 Inter-observer reliability in tool utilisation: 
Inter-rater agreement (in the form of ICCs) is shown in table 13. Overall, agreement was 
higher in meetings scored in real-time compared to those scored retrospectively based on 
video-recordings – the ICCs between the 2 blinded assessors showed this pattern in 7 out of 
the 12 elements of the scale.  
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Table 13: ICCs across all chairing items in both real-live and video recorded MDT 
meetings 
Measured chair‟s criteria Observed Real -
Live MDT 
meetings         
ICC 
Observed Video-
Recorded MDT 
meetings         
ICC 
Time management 0.91 0.65 
Communication 0.75 0.71 
Team working 0.68 0.76 
Ensure clear treatment plans 0.88 0.79 
Ability to summarize 0.86 0.68 
Case prioritisation 0.74 0.64 
Keeping meeting focused 0.70 0.69 
Facilitate discussion 0.78 0.63 
Conflict management 0.69 0.71 
Leadership 0.71 0.79 
Creating good work environment 0.63 0.67 
Recruiting for clinical trials 0.79 0.88 
 
 
8.4.4 Correlational analysis 
To further validate the tool, the individual components of the chairing tool were correlated 
with the mean scores of the chairing tool (overall) and MODe Chair (i.e., the chair‟s 
contribution to the MDT meeting discussion as measured by MODe). In relation to the 
chairing tool, the team working and communication appeared to correlate the highest, while 
in relation to MODe Chair, the abilities to summarise, prioritise cases and keep the meeting 
focused reached the highest values. Full results including correlation coefficients and 
significance levels are shown in Table 14. 
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Table 14: Pearson correlations between the chairing tool and MDT-MODe 
 
 
      
8.5 Discussion 
8.5.1 Summary of findings 
To the best of my knowledge, this is the first attempt to develop and evaluate a tool to assess 
the MDT meeting‟s chairperson skills. The process and the steps of the tool development 
ensure that the assessment tool is evidence based, validated by experts, and can be reliably 
used by assessors. This study relied on experts to validate the content of the tool. The revised 
version of the tool showed content validity and internal consistency. The two observers 
statistically agreed on ratings of chairing characteristics. Reasonably reliable assessment was 
demonstrated for all the 12 domains of the tool in both real-time MDT meeting assessments 
Tool Item 
Chairing tool  
 
(overall mean score) 
 MDT-MODe Chair 
contribution  
 (mean score) 
Chairing tool Time management 0.322 0.405 
 Communication  0.882** 0.315 
 Team working 0.901** 0.514 
 Ensure clear treatment plans 0.445 0.474 
 Ability to summarise 0.844** 0.697** 
 Case prioritisation 0.684** 0.531* 
 Keeping meeting focused 0.782** 0.518* 
 Facilitate discussion 0.816** 0.405 
 Conflict management 0.558* 0.216 
 Leadership 0.815** 0.466 
 
Creating good working 
environment 
0.429 0.146 
 Recruiting for clinical trials 0.759** 0.286 
 
Recruiting for clinical trials 
Overall (mean) 
0.759** 
1.00 
0.286 
0.617* 
MODe Overall (mean) -.196 .207 
Note. N = 15. Two-tailed. *p < 0.05. **p < 0.01.  
 
 
 
118 
 
 
and video-recorded MDT meeting assessments, though the former were more reliably scored 
than the latter, perhaps indicating some limitations of scoring teams on video.  
Furthermore, the overall chairing showed the strongest association with the non-technical 
skills, i.e., team working and communication. These are immensely important aspects of an 
effective healthcare team since their breakdown is a major contributor to medical errors and 
adverse events.[122-124] Thus, a tool that is able to measure these factors will allow different 
cancer MDT meetings to capitalise on efficacy and safety. What is more, chairing tool 
showed positive relation with the chair‟s contribution to the meeting as measured by MODe. 
In particular, the strongest positive association with the chair‟s contribution was detected 
with the chair‟s ability to summarise, prioritise cases and keep the meeting focused (as 
measured by the chairing tool). This points to an important aspect of the chair‟s role within 
MDT since the increase in their involvement signifies gain in the effective case-by-case 
management commonly associated with optimal quality and cost-effective outcomes.[125, 
126] 
 
8.5.2 Limitations 
This study has to be interpreted within its limitations. The survey sample was a sample of 
convenience consisting of attendees of the Prostate Cancer UK summit workshop, however 
the number of respondents (68% Consultants) and their geographical distribution allow at 
least some national representation. There was a discrepancy of the ICC between the real-live 
and video-recorded MDTs. This perhaps can be explained by the videos not being recorded 
for this purpose and the quality of sound was not ideal in some videos – or it could also mean 
that video-based assessment is harder to accomplish reliably. Finally, the 12 domains of the 
tool represent the items that are reported in the limited literature about the desired criteria of 
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an effective MDT chair, followed by expert review – however, a larger scale study is needed 
to find out if there are other criteria that should be considered.  
 
8.6 Conclusion 
The MDT chair plays a key role in the smooth and effective functioning of the team and their 
meeting. Several authors have discussed the attributes and characteristics of an effective 
MDT lead – including the ability to encourage full participation of all team members and 
good communication skills.[25, 40] In a national survey in the UK of more than 2000 MDT 
members, the majority of respondents listed non-technical skills such as assertiveness, good 
communication skills and being a team player, and a minority listed clinical or technical 
expertise as a quality on the qualities that make a good MDT chair/leader.[19]  
 
In this study, I developed an MDT chairing tool – aiming to produce a validated, reliable and 
evidence based tool, to assess the quality of the MDT chairperson in managing the team. The 
tool has been submitted to some testing so far across different surgical specialties with 
adequate reliability and validity evidence – clearly more is required in the future. Moreover, 
the association between the chairing, and the communication and team working  was found to 
be particularly high,  while the abilities to summarise, prioritise cases and keep the meeting 
focused were of particular significance in relation to the chair‟s contribution to the meeting 
(as measured by MODe). This tool, as it stands, can be the foundation of the development of 
an assessment toolkit and a start into training MDT chairs and leads for non-technical skills 
necessary to run more efficient MDT meetings.  
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9 Discussion 
 
Here, I will first discuss the aims I set out in chapter 1 and my attempt to achieve them via 
the studies reported in chapters 2 to 8. I will then discuss the limitations of my research and 
more broadly of this approach to evaluating and improving MDT performance. I will 
conclude with the implications of my research on clinical practice and research directions to 
be explored in the future.   
 
9.1 Review of my aims and what I achieved: 
 
9.1.1 To evaluate the available evidence on the efficacy of MDT decision making and 
decision implementation (chapters 2 and 3). 
 
Evidence suggests that there is no a single way to evaluate the efficacy of an MDT. Despite 
the existence of a „peer review‟ programme as a quality assurance in the UK. Team 
functioning and the decision making process are not really covered by the peer review. In 
chapters 2 and 3, I demonstrated through a systematic review and a large retrospective study 
that there are shortcomings in the Input (i.e. information) that affects the Process of the MDT 
meeting (i.e. decision making) and in turn can be detrimental to the Outcomes of the team 
(i.e. decision implementation). Specifically, the systematic review (chapter 2) showed that 
discordance rate varies from 3 to 33.8% across specialties (non-urological) and the main 
reasons for that are new information/deterioration of patient‟s health or ignoring patient-
related factors/ preferences in the decision making process. In the study presented in chapter 
3, I analysed one year of MDT data in Urology and found that the MDT do not reach into a 
decision in 10% of the cases, mainly due to lack of investigation results. In the same dataset, I 
also found that 11% of the MDT decisions do not get implemented. 
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The straightforward function of the MDT meeting is to decide on the appropriate treatment 
for the patient. An appropriate treatment surely is one that the patients can have, taking into 
account all the variables surrounding their circumstances of psychosocial factors, 
comorbidities as well as their preferences. As a result of lacking of the necessary information 
(Input), reaching a treatment option is neither always possible, nor are the team‟s 
recommendations always right for the patient. As a consequence, the MDT decision is then 
subject to change, eventually resulting in significant treatment delays for the patient. 
 
9.1.2 To assess the views and experience of the MDT members (clinical and non-
clinical) on the efficacy of the MDT meeting (chapters 4 and 5). 
 
In chapter 4, I assessed the views of clinical members of urology and colorectal MDTs 
through semi-structured interview regarding making and implementing treatment 
recommendations. The 22 MDT members agreed on the convenience of the venue of their 
MDT, but had problems with the video-conferencing facility across sites. They reported that 
decisions could not be reached in 8% of the discussed cases due to inadequate information, 
unavailability of an MDT member, time pressure or technological problems. Those 
interviewed also thought that only 5% of their MDT decisions do not get implemented – for 
reasons similar to what previous studies showed, i.e. ignoring patient related factors and 
disease progression.  
 
In chapter 5, I extended the themes from chapter 4 to assess the views of the non-clinical 
MDT members (MDT coordinators). I conducted a survey of a national sample of MDT 
coordinators across different specialties. Only half of the 265 respondents had the title of an 
MDT coordinator and about 38% felt that they had a disparity between their job plan and 
their actual duties. They attributed not reaching into a decision at the MDT meeting to, 
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unsurprisingly, lack of investigation results and non-attendance of a key MDT member. The 
findings of this study indicate that the coordinators‟ job involves high workload, it involves a 
high load of administrative work and most of them are either not trained or have educational 
needs that are not addressed yet. 
 
9.1.3 To explore the views of core MDT members on how to improve the functionality 
of the MDT meeting (chapter 6). 
 
In this chapter, I explored the views of the participants of 2 national Uro-oncological 
meetings comprising Urologists, Oncologists and CNSs about the usefulness and time-
effectiveness of the MDT meeting within the cancer care pathway.  Oncologists tended to 
spend more time attending MDT meetings compared to Urologists – likely because they 
attend different tumour MDTs and they cover different specialties. Respondents thought that 
the time spent in the meeting helps both their own patients and their colleagues‟ patients. 
Urologists, however, reported that the MDT is more useful for their colleagues‟ patients. The 
main themes that emerged from the survey in terms of time saving were: formulating a plan, 
aid in deciding of appropriate investigations during out-patient consultation. A key aspect of 
the survey was whether all cases should be discussed at the MDT – and whether alternatives 
to this approach exist. It is mandatory to discuss all suspected and diagnosed new cancer 
cases by the MDT meeting, however, whether recurrent disease would benefit from such 
practice is questionable as those recurrent cancers are more complex and carry a high 
symptom burden. A recent study showed that 79% of Urology MDT members agree that all 
cancer patients with recurrence should be discussed by the MDT.[33] The survey discussed 
here showed similar results as a way to benefit the more complicated and advanced disease 
cases. However, including all recurrent and advanced disease in the MDT meeting would add 
even more load on the MDT meeting. Respondents argued that some cases could be excluded 
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form discussion such as non-muscle invasive bladder cancer and low grade prostate cancer 
cases. Aiming to improve the case discussion process, participants further suggested that 
cases could be prioritised by complexity or tumour type, but prioritisation by team members‟ 
availability was less popular. In contrast, participants generally did not agree that the MDT 
meeting could be split into smaller meetings neither by complexity, tumour type or by team 
members‟ availability.  
 
9.1.4 To develop methods to assess the “input-process” of the MDT meeting by 
focusing on the factors influencing the MDT outcome, i.e. preparation, teamwork 
and leadership (chapters 7 and 8). 
 
The end stage of the MDT Process in the context of the „Input-Process-Outcome‟ approach 
that I presented in chapter 1 of this thesis is to reach into a recommendation. Broadly, there 
are 2 factors that are necessary in order to reach this stage. One of them is the information 
about the disease and the patient including investigation results (an Input). The second one is 
the expert opinion and review of the team members, i.e. their contribution to the case 
discussion (a Process). In chapter 7, I used a tool to assess both Input and Process aspects of 
the MDT meeting and how the assessments relate to the outcome of the meeting, i.e. reaching 
into a decision.  
 
The study showed that different MDT meetings differ in caseload. Some MDT meetings 
discussed 9 patients (Head and Neck MDT), whereas in others the caseload reached into over 
50 cases such as in Urology MDTs. It was observed that 10.8% of the cases did not have a 
decision made at the end of the meeting - similar finding as in chapter 3 (10.2%). Again 
reasons for not reaching into decision included lack of investigation results and unavailability 
of a core MDT member in the meeting. In this particular study, another factor came forward: 
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lack of time. I believe this is where a case load can impose a pressure in some MDT meetings 
(like in Urology). The study further showed that observational assessment using a systematic 
tool like the MDT-MODe were reliable and importantly reflected whether a decision is 
reached or not – a finding that adds further validation to such observational assessments. 
Finally, I also validated MDT MODe to observe video-recorded MDTs as well as in vivo 
observations for the first time.  
 
From my experience and during attending MDT meetings, I noticed that there were occasions 
that a decision was made and that was obvious from the presenter documenting the decision 
in the MDT proforma, but I as an observer and a junior trainee was not aware what that 
decision was. This was affecting the coordinators‟ work, as they were trying to update the 
MDT minutes during the meeting so this made them to transfer the information after the 
meeting from the MDT proforma. This raised the issue of the educational duty of the MDT 
meeting for the attendees, especially the juniors. I also noticed that often when cases are 
discussed, the presenter had not met the patient before, which delayed the discussion by 
looking into the notes searching for information about the patient such as psychosocial issues 
and fitness for a certain treatment. These two objective observations were added to the MDT-
MODe in my revisions to the tool. 
  
A further observation of mine, which triggered the study of chapter 8, was the variability of 
the leadership skills of the chairperson running the meeting. In order to run such meetings, 
certain skills are critical for the chairperson. These became the focus of chapter 8, where I 
developed an evidence based tool to assess the MDT chairperson. The desired and expected 
chairing criteria were extracted from the literature and also from expert opinion. The tool was 
content validated, correlated positively with the leadership scale of the MDT MODe, and 
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showed adequate inter-rater reliability in real time and video-recorded MDT meetings. 
Further research is required to validate the tool and make it useful in the context of 
chairmanship/leadership training – however this tool represents an initial systematic and 
evidence based attempt to address this gap.  
 
9.2 Limitations  
 
There are some limitations to this research – and to the wider field of improving the quality 
of MDT working via multi-method studies such as those I report in this thesis. As the concept 
of integrating the MDT in the cancer pathway is already established in many countries and 
mandatory in others like the UK, it is not possible to conduct trials in order to study the 
effects of the MDT meeting, as opposed to no MDT meeting discussion in the cancer 
pathway, in the context of decision making, decision implementation and timing of receiving 
treatment. 
 
Limited evidence in the literature is another limitation of this research. Despite this so far, the 
function and effectiveness of the MDT meeting have been assessed against different criteria. 
The outcome measure i.e. survival that has been used in some of the recent studies to assess 
the functionality of the MDT meeting using 3 and 5 year mortality are rather basic measures 
as they may be objective and are also multifactorial so using them to explain success or 
failure of interventions which the introduction of the MDT meeting in the cancer care in this 
case, is likely to be problematic and non-conclusive. There is a limitation of the evidence 
available in the literature in the researched area of MDTs (the implementation of the MDT 
decision). There is a limitation in the evidence base in every speciality too about the MDT 
outcome measures. In urology, there is no study in the literature looking at the concordance 
of the MDT decision. 
126 
 
 
Self-report has many advantages however they suffer from some disadvantages. There is a 
validity limitation as the respondents may exaggerate the situation and there is the 
unavoidable inclusion of the person‟s feeling s at the time of the interview or answering the 
questionnaire. A second limitation to self-reported studies is that the sample size is limited to 
the voluntary respondents and its associated bias if there is a systematic difference between 
the included sample and the non-respondents group. 
 
Similarly, observational studies that have been used in this research also have disadvantages. 
Limited time is one, the time allocated for MD (Res) programme is limited and data 
collection is time and resource demanding. In addition, other potential weaknesses of 
observational studies include the observer bias and the Hawthorne effect (observer effect) 
where the presence of the observer may affect the behaviour of the observed party. Further, 
another limitation of the observational studies is that they are time consuming and require 
observers to be trained. I used 2 observational tools to assess the MDT function: the MDT 
MODe to objectively assess the information that was brought to the meeting and individual 
member‟s contribution to the discussion. The second tool was the MDT chairing tool. The 
latter tool was developed to assess the chairing and leadership skills of the MDT chairperson. 
Both tools are objectively capturing performance information including non-technical skills 
of the MDT members together with the chairperson. The limitation I experienced using the 
tool with other raters was that every evaluator differs in rating and assessing others despite 
the existence of anchors for the ratings. This is can be reflected in the learning curves 
demonstrated in chapters 7 and 8. This takes us back to the fact and a finding of a recent 
study quoting that assessors of non-technical skills should be trained first.[106] 
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9.3 Implications of my research and future directions   
 
For research purposes, my findings have implications for future work in this field. One area 
of interest is different ways to evaluate the quality of MDT working using parameters other 
than survival. It would be interesting to look at whether the MDT approach has improved 
compliance with guidelines. As I mentioned in the introduction, the efficacy of an MDT 
could be assessed via their adherence rate with available guidelines. I believe that this is an 
area that needs exploring as there is lack of evidence base on this and there are only few 
small scale studies in the literature. During my research, I also became aware that there is no 
systematic arrangement in place to ensure that eligible patients are highlighted for 
recruitment into clinical trials. Generally, MDT meetings with a research nurse present tend 
to do better from what I experienced first-hand. Recruitment into clinical trials is one of the 
functions of the MDT meeting. It has been underlined also in the „Characteristics of an 
effective MDT‟ report.[28] 
 
Another neglected area and one of the key MDT functions is the education duty of the MDT 
meeting. Research should focus on the barriers and obstacles facing the MDT (and the 
meeting) in delivering such an important function. A specific finding of my research 
highlights the educational needs that some of the non-clinical members of the MDT have. 
Further research can explore these needs and evaluate the impact of better-trained 
coordinators on the running and of the MDT and the coordination of care across the cancer 
pathway more broadly. Beyond the non-clinical members, MDT leads and chairs seem to 
perform variably as well, and it seems that there are no set criteria at present for individuals 
to be able to run those meetings. The clinical knowledge is not what was highlighted in my 
research, but rather a set of non-technical skills. Such skills should be included in theoretical 
and practical training. The elements of the newly developed instrument of chapter 8 could be 
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used to train MDT chairs and leads – with the hypothesis to be tested that better trained 
chairs/leads contribute to more effective meetings and decision making.  
 
For clinical practice purposes, the assessment tools used within this thesis can be used in 
practice to assess both the performance and the efficacy of MDT meetings. These 
assessments can form a part of a toolkit to assess the functionality of the MDT and also for 
team self-reflective purposes. Members can improve the „Input-Process-Outcome‟ elements 
of their meetings through intervention – depending on what is locally needed. The studies I 
have presented in this thesis show that experienced MDT members are aware of the function 
and the shortcomings of their MDTs. Thus self-assessment, perhaps with some external 
facilitation if needed and/or available, may provide a positive step to enhance the 
functionality of cancer MDTs as a first stage. I do not envisage such a process as „competing‟ 
in any way with the established „peer review‟ system – but rather as a complementary process 
with a focus on teamworking and team leadership elements.   
 
In the recent years, there has been an emphasis on training of non-technical skills alongside 
technical skills – particularly within the context of surgery. Surgical oncology, especially 
MDT driven care, seems to now be following the same path. Although more work needs to be 
conducted in this area, improvement in MDT processes can enhance teamworking, and 
decision making, and can lead to improved timeliness in cancer care. Ultimately, these 
improvements ought to be linked to enhanced patient satisfaction and improved patient 
reported outcomes and eventually the quality of the delivered care. 
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Appendices 
 
Appendix 1: Abstracts of published articles 
 
Chapter 4- Factors that can make an impact on decision-making and decision 
implementation in cancer multidisciplinary teams: An interview study of the provider 
perspective 
BACKGROUND: It is becoming a standard practice worldwide for cancer patients to be 
discussed by a multidisciplinary team (MDT or 'tumour board') in order to formulate an 
expert-derived management plan. Evidence suggests that MDTs do not always work 
optimally in making clinical decisions and that not all MDT decisions get implemented into 
care. We investigated factors influencing decision-making and decision implementation in 
cancer MDTs.  
METHODS: Semi-structured interviews were carried out with expert MDT members of 
Urological and Gastro-Intestinal tumours of 3 London (UK) hospitals. The standardised 
interview protocol assessed MDT experts' views on decision-making, barriers to reaching a 
decision and implementing it into care, and interventions to improve this process. All 
interviews were audio-taped, transcribed verbatim and analysed using a standardised 
approach. Emergent themes were identified by 2 clinical coders and tabulated.  
RESULTS: Twenty-two participants participated in the study and data collection achieved 
'saturation' (i.e., similar themes raised by different participants). Barriers to clinical decision-
making included: inadequate clinical information; lack of investigation results; non-
attendance of key members; teleconferencing failures. Barriers to implementation of MDT 
recommendations included: non-consideration of patients' choices or co-morbidities; disease 
progression at the time of implementation. Proposed interventions included improving the 
information available for the discussion through a standardised proforma; improving video-
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conferencing; reducing the MDT caseload (e.g., via selective MDT review of certain 
patients); and including patients more in the decision process.  
CONCLUSIONS: There is an increasing drive to improve the clinical role of the MDT within 
cancer care. This study demonstrates the main barriers that MDTs face in deciding on and, 
importantly, implementing a management plan. Further research should prospectively 
evaluate interventions to enhance translation of MDT decision-making into cancer care and 
thus to expedite and improve care. 
 
Chapter 5- The cancer multi-disciplinary team from the co-ordinators' perspective: 
results from a national survey in the UK 
ABSTRACT: BACKGROUND: The MDT-Coordinators' role is relatively new, and as such 
it is evolving. What is apparent is that the coordinator's work is pivotal to the effectiveness 
and efficiency of an MDT. This study aimed to assess the views and needs of MDT-
coordinators.  
METHODS: Views of MDT-coordinators were evaluated through an online survey that 
covered their current practice and role, MDT chairing, opinions on how to improve MDT 
meetings, and coordinators' educational/training needs.  
RESULTS: 265 coordinators responded to the survey. More than one third of the respondents 
felt that the job plan does not reflect their actual duties. It was reported that medical members 
of the MDT always contribute to case discussions. 66.9% of the respondents reported that the 
MDTs are chaired by Surgeons. The majority reported having training on data management 
and IT skills but more than 50% reported that they felt further training is needed in areas of 
Oncology, Anatomy and physiology, audit and research, peer-review, and leadership skills. 
CONCLUSIONS: MDT-Coordinators' role is central to the care of cancer patients. The study 
reveals areas of training requirements that remain unmet. Improving the resources and 
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training available to MDT-coordinators can give them an opportunity to develop the required 
additional skills and contribute to improved MDT performance and ultimately cancer care. 
Finally, this study looks forward to the impact of the recent launch of a new e-learning 
training programme for MDT coordinators and discusses implications for future research. 
 
Chapter 7- Validation of team performance assessment for multidisciplinary tumor 
boards 
OBJECTIVE: To construct validate the 'Multidisciplinary Tumor Board Metric for the 
Observation of Decision-Making' instrument (MTB-MODe), to evaluate assessors' learning 
curves, and to evaluate its feasibility and inter-rater reliability for assessing the decision-
making process of video-recorded MTB meetings.  
BACKGROUND: MTBs are becoming the standard practice in managing cancer patients 
internationally - however, there are no agreed standards to assess the efficacy of such teams. 
The MTB-MODe tool assesses the process of MTB decision-making via standardized 
observation (1-5 anchored scales) of the quality of information presented at the MTB and 
MTB-members' contribution to case review.  
METHODS: A total of 683 MTB case-discussions were assessed using MTB-MODe in a 
multi-phased study: 332 cases (9 urology MTBs) by 1 urologist in vivo; 224 cases (6 urology 
MTBs) by 2 urologists in vivo. The instrument was refined and subsequently used to rate 127 
cases of eight video-recorded MTBs of five different tumor types.  
RESULTS: Good inter-rater reliability was achieved in vivo and transferred to the video-
recorded MTB meetings that remained consistent (Intra-Class Correlations>/=0.70). MTB-
MODe scores were higher in cases that resulted in a decision (mean=2.54, SD=0.47) than 
cases where no decision was reached (mean=2.02, SD=0.65) (P</=0.001).  
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CONCLUSIONS: A standardized method to assess the quality of MTB working can enhance 
the quality of cancer care and the ability of MTBs to evaluate their own performance enables 
promotion of good practice. Video recordings offer a feasible and reliable method of 
assessing MTB working. 
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Appendix 2: Detailed search strategy of the systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Search terms Ovid( Embase, 
Medline and 
PsycINFO) 
CINAHL Cochrane Pubmed 
1 (malignan* or cancer* 
or neoplas* or 
tumour* or tumor*). 
 
2720002 80163 78980 2682916 
2 MDT  OR  MCC  OR  
MCT  OR MDM  OR  
MCM  OR  
multidisciplinary team 
OR patient care team 
OR tumor board. 
 
90385 9290 6812 871692 
3 Decision OR decision 
making OR decision 
implementation 
 
228397 28046 21427 180277 
4 1 AND 2 AND 3 1934 89 1702 
(MeSH=1) 
4955 
5 limit 4 to English 
language & Human 
1662 
(MeSH=100) 
17(LIMIT 
EXCLUDING 
Medline) 
N/A 4632 
 Total 1762 17 1703 4632 
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Appendix 3: Topic guide for the interview study 
 
1. Introduction  Introduce myself 
 Thank them for taking part. 
 Introduce project – State aim of the interview 
 Timing of the interview: is about 20- 30 minutes 
 Ask permission to tape-record the interview, assure anonymity 
and confidentiality ( sign consent and start recording), tell them 
that you will make notes 
 Establish ID of who I‟m speaking to( demographics):  
o Sex:          M              F 
o Speciality and grade: 
o Years in that grade: 
 
2. Identify present 
system  
 I would like to talk to you about multidisciplinary team meeting 
in urology/GI Surgery    
     
 Do you attend MDTM? (How many? How often?) 
 
3. Venue and 
Environment 
 Where is the MDT meeting that you attend held? 
 
 Do you have video conferencing? 
 
 How does video conferencing affect communication compared 
to face to face? 
 
 At the MDTM are there problems with equipment/IT? (Does 
this affect the meeting and the decision making process? Can 
you give examples?) 
 
 Does this affect the decision making? 
 
4. Decision making  Is there always a clear treatment plan from the MDT meeting on 
every patient? 
 
 What percentage of cases will have a clear plan post MDTM? 
 If not, why not? 
 
 What are the implications of not reaching a decision? ( on 
patient, MDT, NHS) 
 
 What could be done to improve that? 
 
5. Implementing 
decision 
 Does the decision always get implemented? Yes or No? 
 If not, why?( reasons for non-implementation) 
 Any idea of how many decisions get implemented/not 
implemented? % 
 
 What are the implications of not implementing a decision? ( on 
patient, MDT, NHS) 
 
 What could be done to improve that? 
 
 
 
 
 
6. Questions to be 
asked in the 
decision making 
and decision 
implementation 
section( do not 
duplicate) 
 At the MDTM is every patient‟s case History presented?  
Who presents? 
 Is it useful? Is it complete? Do have trust/faith in what is 
presented? 
What are the possible problems, or problems you‟ve 
encountered in your experience?) 
 How are cases for discussion booked? (What info is needed, 
are there any criteria?) 
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 What format is the information available in?  
Are the notes present? 
 Is there a summary? 
 Is it prepared beforehand? By whom?  
Is there and aid to help bringing the right information? 
 At the MDTM Are the x-ray images presented? (For all 
patients or certain ones?) Elaborate on the answer. 
 
 At the MDTM Are the path slides presented? (For all patients 
or certain ones?) Elaborate on the answer. 
 
 At the MDTM are the patients‟ other problems presented? 
(Morbidity and psycho-social problems or issues) Whom by?) 
 
 At the MDTM Are the patient‟s wishes presented? Wishes in 
general, or for specific treatment options. 
(Who knows them? Whom by?) 
 Is the clinician who knows the patient, present always in the 
meeting? 
 
 How long is the MDT? 
 
 It there enough time to discuss all cases? 
 
 At the MDTM is there a chair person?  
 
 Does the chair enhance decision making? How? 
7.  Improvement  What do you find good about MDTMs? (ask for examples) 
 
 What are the problems with the MDTM?  
 
 Can you identify/ suggest one thing that would make your MDT 
decision making and implementation improved? Is there 
something you would change? 
 Ask about recruiting to trials 
 
8. Questions  Do you have any questions? Anything else you would like to 
add?  
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Appendix 4: An example transcript from the interview study 
 
For the purpose of the transcribing company, this is Mr………………, and your 
speciality and grade? 
 
Uro-oncology consultant. 
 
Consultant. How many years have you been in this grade? 
 
One. 
 
So we‟ll talk about MDT, mainly urology MDTs.  How many MDTs do you attend a 
week? 
 
Two, two. 
 
Two.  And they are? 
 
UCH and one at Bart‟s, and they‟re uro-oncology MDTs. 
 
Okay, and do you get, are they, are they held in a dedicated space, a venue? 
 
Yeah, they‟re both held in a, a lecture theatre type of, or a large office type of space. 
 
And do you have video conferencing? 
 
We have video conferencing. 
 
In both? 
 
Yeah. 
 
Do you think there‟s, how, how does this video conferencing affect mainly decision 
making compared to face to face discussion? 
 
I, I think it‟s, it‟s more difficult because there are a lot of problems, as you know, with, with 
actual, the videos themselves or the, the teleconferencing in that, you know, some of the time 
you can‟t hear what they‟re saying on the other side.  There‟s a lot of mumbling going on, 
there‟s a lot of static, sometimes it cuts out.  So it, it is much more difficult to do it in that 
setting.  But it, obviously it‟s not practical for – 
 
Everybody? 
 
Hospitals which are, you know, a long way away to centralise it to one, to one area either.  
And, and also I think it‟s more difficult to get, get, to get more, to get opinions across on 
teleconferencing, sort of, you know, strategy. 
 
Okay, and do you see a conflict between B sites(?), what if there is a? 
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Yes, and this is, actually, I saw one of the questions, this is, what I think, one of the reasons 
why MDTs aren‟t ideal, because every surgeon, radiotherapist, or whoever it is – 
 
All team up? 
 
Has their own bio, has their own bio section.  And often every unit, depending on their sub-
speciality, what they, what procedure they specialise in, have their own bias towards a certain 
procedure. 
 
I mean, certainly you mentioned you had problems with the, with the IT and video 
conferencing? 
 
Yeah, yeah. 
 
Did you have delays, at all, in (overspeaking)? 
 
Yeah, we‟ve, we‟ve often had delays.  In fact… the, the most problematic one, the one I sit at 
at Bart‟s, it cuts out every hour, so the units have to be reconnected after an hour.  So you get 
a two minute break there, and a lot of the time the, the IT, especially at the Bart‟s site breaks 
down.  The, the imaging, the PACS system, so you can‟t see any images, so – 
 
Oh, I see, and, and that, that kind of thing affects the decision making process? 
 
Yeah.  And, and, easiest example is last week, but we had no radiologist.  Not this last week, 
the week before, for two weeks in a row we had no radiologist, so actually all that happened 
we was had to cancel the, anything which needed a radiology opinion.  In fact, which is pretty 
much everything, it‟s the whole point of the MDT (laughter). 
 
True, true.  Well, we‟ll shift to one of the main cores of this questionnaire which is 
decision making.  Do you think 100% of the cases are discussed in the MDT get a 
decision? 
 
No.  Some are deferred, because – 
 
Okay, well, I, I, I name(?) then, deferred are not decision made, so then – 
 
Okay, yeah. 
 
Okay, so can you give us a rough idea percentage wise? 
 
I would say 5%. 
 
5% are not getting decisions.  And these are reasons? 
 
Either the appropriate – 
 
I mean, you mentioned a few. 
 
Yeah, appropriate investigations not being available, the… problems with the IT.  Also that 
there can be a conflict of opinion, and actually they go away having to have more 
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investigations or, and come back the following week.  It‟s not just missing investigations, 
they need more investigation before we can make a decision. 
 
And, what, in terms of information available to the MDT, like patient history, let‟s say, 
do you, from experience, did you have any problem with them at all, in, in? 
 
Yeah, because the majority of patients that we discuss at the MDT, the individual surgeon or 
the clinician will not have seen them.  So we will only personally know about, say, 10% to 
20% of the patients presented at that MDT.  And the other 80% to 90% will be patients that 
we have never actually seen, personally.  And if the full history is not there, which often it 
isn‟t, I think, it‟s, well not often I would say, but a significant number of times it‟s not.  We, I 
think we make decisions with implications about the history, we don‟t know their comorbid 
state, often, we don‟t know about the patient‟s comorbidity.  So we may be recommending a 
radical prostatectomy without actually knowing that they‟ve had freak allergies.  So that sort 
of history tends to be missing, but actually the, the work involved in getting that history is a 
lot of work.  You need, I, I think if you‟re going to do that for the number of patients that we 
have at the MDT that each hospital probably needs one junior dedicated, half their time at 
least, half the week, just gathering that information, and it‟s, that‟s not practical.  
 
So, I mean, the information aren‟t complete? 
 
Yeah. 
 
Who‟s, who‟s preparing your summaries, I mean? 
 
Our registrars prepare the summaries. 
 
So your… your cases are prepared by your registrar? 
 
Our registrars, yeah. 
 
Okay, and is that, is there a, a proforma or a, a, something to prepare? 
 
There‟s no proforma, no, nothing – 
 
Nothing agreed? 
 
No, but it‟s not – 
 
So depending on experience? 
 
It depends on experience, so if you have a first year registrar preparing it, it‟s, often the MDT 
is very slow.  Whereas if a Fellow is preparing it, it, it‟s much, the histories are much shorter, 
to the point. 
 
X-rays, are they, like images, are they always, I mean, you mentioned there is a media 
problem(?)? 
 
Yeah, sometimes there‟s a, there‟s a problem with the images or the, the PACS system or the 
x-ray system and you can‟t get the images up.  But otherwise – 
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And that sounds the reason. 
 
Yes. 
 
Is that a reason to not, to reach a decision? 
 
Yeah, that‟s often, that‟s it, we, we will cancel the case, if images aren‟t available – 
 
So defer to next? 
 
Or histology is not available, which happens as well.  Then the patient, no decision is made 
that week.  And, you know, a lot depends, thinking of the histopathologist as well, a lot 
depends on the workload he receives that week.  And also when he was asked, the same with 
the x-ray, the radiologist, when they were asked to, to prepare the images or the 
histopathology.  If they were asked at the last minute, then those patients will not be 
discussed, because they won‟t have had time to go through the images or the histology prior 
to that. 
 
Okay, path slides do you have path slides presented?  The slides themselves? 
 
Yes, we have the slides. 
 
Okay, do, do you, do you see any point in presenting the slides, apart from being 
educational? 
 
I was a histopathologist for two years so I, I think there is. 
 
Okay, so are you (laughter), you, you‟ll be biased, yeah? 
 
Yeah, I‟m biased, so I think there is.  The, at the UCH we have slides presented, the 
pathology slides, and Bart‟s we don‟t.  And I actually think, at Bart‟s, because the pathologist 
is reading out his report, rather than reviewing a slide it feels an incomplete MDT.  And I 
think I, maybe that‟s just for educational purposes.  But the MDT is not just about decision 
making, it‟s also about education, the juniors are sitting there, the, the nurse specialists are 
sitting there, consultants are there.  So, you know, I feel that there‟s some lack of education 
there. 
 
Patient‟s wishes.  Are they presented in the MDT? 
 
Very rarely. 
 
Very rarely, so the, the standard you do, decide on a patient and then you discuss with 
them and then – 
 
And then discuss with them. 
 
You‟ll, you‟ll see his wishes? 
 
Yeah. 
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Do you think if they are addressed in the meeting the decisions will be more accurate? 
 
Yeah.  If we knew what the patient‟s bias or opinion was, I think we would come out, it 
would save time actually, it would save time.  That, we wouldn‟t necessarily have to go back 
and have another discussion and say, “actually we‟re giving you these three options.”  We 
could probably just say, “actually we agree.  Then actually we can go ahead with whatever 
you want to go ahead with.” 
 
You mentioned some of the people you‟d been discussing, you haven‟t seen before, 
probably your registrar have seen or somebody else on the team has seen.  What about 
attendance of the person who knows a patient? 
 
That‟s – 
 
Is their case being discussed without? 
 
Yes.  Which is, so that the consultant often only knows about 10% to 20% of the patients.  
And often a patient is presented who no-one at the MDT has seen before because someone 
may be away.  The person who dealt with them may be on holiday, on study leave, or 
whatever.  And so that does happen quite often.  And also the nurse specialist puts on cases at 
the MDT and they‟re not there for every MDT. 
 
What about the time for the MDT?  How long does your MDT normally last? 
 
Usually about… an hour and a half at UCH and about two and a half hours at Bart‟s. 
 
Is it enough time to discuss everybody? 
 
Yes it is, yeah. 
 
Is there a chair person in the MDT? 
 
Yeah. 
 
Is that a fixed chair or it rotates? 
 
It‟s… it‟s, yeah, I, it‟s a, I think at the, the UCH site it‟s a fixed chair and it will only rotate if 
that person is away. 
 
Is it a surgeon or is it an oncologist? 
 
It‟s a, at the moment it‟s a surgeon. 
 
Surgeon, okay? 
 
Yeah.  At the Bart‟s site it‟s not, tends to be, I‟m not sure actually, it‟s a bit confusing 
actually, who actually chairs it (laughter). 
 
Let‟s comment on the UCL then, if you, if, if there‟s a confusion on that. 
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Yeah. 
 
Do you think the chair enhances the decision making in, in? 
 
Yes it does.  I, I think it focuses it, gets through the case quicker, focuses the discussion.  And 
the time for discussion is much shorter. 
 
So bring back everybody to the? 
 
Yeah, to the (inaudible 00:10:36) 
 
I‟m going to show you one of the, our, well, draft preparing MDTs.  I mean, this is 
cancer specific, prostate kidney and bladder.  And then comorbidity and psycho social.  
Do you think such a proforma, which is available for everybody preparing the cases, is 
a, is a helpful prep? 
 
It would be helpful, prep, but just looking at this, it looks, well – 
 
Too much? 
 
It‟s too much.  And I think, as I said earlier, if we‟re going to do this, which would be ideal, 
then you actually need one junior to spend half his week preparing these cases.  Because 
there are a lot of cases at the MDT, often there are 100 cases.  So, yes they may be from 
different hospitals, but there may be a junior at each hospital preparing, say, 30 of those.  And 
the prepare 30 cases in this sort of detail, that‟s a lot, lot of time. 
 
Although it is cancer specific, so patients got cancer, prostate, he don‟t need to fill them 
out, he just one and this, these two.  And probably he, if, if you – 
 
But even then, you know, if a junior is preparing prostate, kidney and bladder, usually it‟s 
only one junior preparing it.  So he‟ll end up preparing the whole MDT.  So, and I think, yes 
it‟s good – 
 
So we need a, probably a shorter, a shorter checklist? 
 
Yeah.  This would be ideal, but I‟m here, I‟m having a look here, which says “blood tests”, 
say for example, I mean, you, I think in that sort of situation you‟re just going to have to 
presume that blood tests are not abnormal unless you‟re told otherwise.  Because otherwise 
he‟s going to be checking every blood test on the computer – 
 
That will take ages. 
 
It‟s, it‟s, I mean, you just can‟t, there‟s no time to do that kind of thing on the NHS.  You 
know, family history, ethnicity, you know, okay, ethnicity you can tell from the name.  But, I 
mean, to be looking at family history and stuff is, if it‟s not readily available it‟s, it‟s not 
easy. 
 
So probably an abbreviated version of that or a tick boxing? 
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Yeah, I think, I think, yeah, it‟s got to be, it‟s got to be abbreviated.  And I think the two 
things which are often missing are the patient‟s opinion, because that will influence the end 
result, and comorbidity.  My personal view is, if you have the patient‟s opinion and you have 
the comorbidity, then what we have right now, with a short clinical history, the pathology and 
the radiology is enough. 
 
Is enough? 
 
Yeah.  So just, I, I would just have the comorbidity and whatever else. 
 
Your wishes, yeah? 
 
And their opinion, I think that‟s important. 
 
If we, if we say we decided on, on a patient, on, on a, we have a plan, and we went out to 
discuss him, to discuss the plan in the, in the clinic.  Do you think all the decisions from 
MDT are, get implemented? 
 
No.  I think – 
 
Percentage roughly? 
 
I think 90% to 95% are implemented.  But you do get 5% to 10% which are overruled.  Partly 
because, I can, in my personal experience, but sometimes you disagree with the MDT.  If I‟m 
away at the MDT – 
 
You mean, you mean the, the treating clinician disagrees, okay? 
 
Yeah, yeah.  So, for example, I was away at an MDT a few weeks ago.  The MDT 
recommended not to treat the person with salvage therapy for recurrent prostate cancer.  They 
hadn‟t seen the patient.  The patient was 81 but he was a very, very fit guy. 
 
Very fit? 
 
No comorbidity whatever, whatsoever.  And the patient wanted treatment, he was insistent he 
wanted treatment.  And that didn‟t come up at the MDT, I was away.  So again, that patient 
opinion was missing and the comorbidity was missing at the MDT and I actually overruled it.  
And I say no, we will, and I documented it.  Obviously you have to then document it clearly, 
that actually the patient wants to go ahead and I agree with him that he should go ahead. 
 
Any other reasons of not implementation?  I mean, probably patients‟ wishes comes 
there? 
 
Yeah, patients‟ wishes, yeah. 
 
Which one, a part of, you? 
 
And comorbidity, yeah. 
 
And so missing information from the start? 
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Yeah, yeah. 
 
What do you think, I mean, going back to the first, the first, the previous question, this 
question, if decision are not made, what‟s the implication on, on the, on the patient and 
on the meeting? 
 
I mean we, well, I think we miss the targets initially, so that‟s important in a hospital, that‟s 
important in – 
 
So fines and charge, okay? 
 
Yeah, financial implications against the hospital, in that targets, but I think more importantly, 
to the patient, illicit(?) delays in their treatment.  Because something like renal cancer, or 
aggressive bladder cancer, if it was a relative of mine, I wouldn‟t want a delay of even a few 
weeks.  So, and I know, yes, it‟s easy to say “we‟ll bring him back next week or within two 
weeks.”  But actually, that two weeks translates into… it, it, it, a much longer delay in the 
long term, because that two weeks, extra to make a decision, then you have to see the patient 
back.  And it, it just added steps in the cycle of, of delays. 
 
Of delays, okay.  Can you suggest anything to improve first, decision making and 
second, implementation?  One thing will, will do. 
 
Sorry, to improve? 
 
So, to improve decision making at the MDT. 
 
To improve decision.  I think it would, just one thing or can I say two things? 
 
Well, you can, you can. 
 
Well I think, as we‟ve said already, put down the comorbidity and that, and if possible, that‟s 
not always going to be possible, the patient‟s opinion.  I think those two things should be 
there.  But also, you have to have a clinician, ideally, who‟s actually seen the patient, I think 
that‟s very, very important.  And, you know, we‟re, we‟re making decisions without actually 
having seen many of these patients. 
 
Do you think these recommendations can apply to improve the implementation as well? 
 
Yes.  Because it will, it will, it will help both…  And also, actually, one other thing is 
documentation at the MDT, occasionally patients get lost.  Just in my own experience, I‟ve 
seen two patients I remember who, who, the recommendation of the MDT was actually that 
they needed treatment, radiotherapy, one of them was radiotherapy for bladder cancer.  Eight 
months later it, it transpired, he came back with metastasis, he‟d never had the radiotherapy.  
So actually, you know, these are odd cases but they have serious consequences at an MDT 
because they‟re all cancer cases.  So I‟m not quite sure that – 
 
How do you, how, how do you record your decision, is it paper or is it data that? 
 
It‟s, it‟s, well it‟s typed up.  But then the, the typing is done by the nurse specialist.  So, or the 
MDT co-ordinator or a combination of both.  So actually, when a decision is made at the 
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MDT, then the nurse specialist and the MDT co-ordinator will get together at the end and just 
confirm that that was a plan.  And then that plan then has to be implemented, and some, you 
know, occasionally patients do get lost in the system.  But maybe, I‟m not quite clear exactly 
where that, where those couple of patients got lost, whether it was – 
 
So they, in the, in the process? 
 
In the process that eight months later, they hadn‟t had radiotherapy, or this one person hadn‟t, 
the other one was a slightly different case.  But again, both presented metastasis and had had 
no treatment. 
 
Do you currently have a database? 
 
Database as in? 
 
When you present cases, is it like, is it written on the screen at all or is it projected? 
 
No, no, it‟s, it‟s typed up and then – 
 
It‟s typed up, okay, in summaries? 
 
Yeah.  I think that‟s an important point to bring up because it, that, that‟s, even though these 
are occasional patients – 
 
Well one is, one is enough, isn‟t it? 
 
Yeah, they‟re, they‟re coming back.  I mean, basically, it‟s, it‟s a missed cancer which has 
metastasised and they‟re, they‟re incurable at that stage.  And the time they were curable.  
And a similar thing happened with the kidney cancer which was meant to be treated, and he 
came back six months later with metastasis.  For some reason, you know, both of them had 
not had treatment.  So I think it‟s a translation from actually – 
 
So, so, so we can, we can add this as a reason for not implementation, I mean, it‟s a very 
significant reason – 
 
Yeah, precisely, yeah. 
 
It‟s very risky, but I‟d say there‟s a big – 
 
It is, it‟s, and I think it‟s, you‟ll see it at every MDT.  Every surgeon will have experience 
with these patients.  And it‟s somewhere at the problem occurring between the MDT making 
a decision and actually either the patient‟s not given an appointment to the clinic, or the, the 
MDT decision is not relayed, or actually the patient DNAs and then no-one follows him up. 
 
Discharge the patient or? 
 
Yeah, exactly, the patient DNAs and actually, you know.  I, I don‟t know exactly where that 
problem was, it could be any of those.  I‟m not sure actually whether we, whether we actually 
ever addressed that. 
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Interesting.  Well, I‟ll ask you another question which is not really related to decision 
making, well it is a bit, what do you think about recruitment for trials in the MDT?  Are 
they perfect? 
 
No, because often, you can only recruit for trials, and I experienced, from my, for example 
you see, at Bart‟s, I recruit for trials which are held at UCH.  But actually, to counsel for 
trials, the patient is seen at Bart‟s or Whipps Cross, but to counsel for the trials, that hospital 
has to be designated as one of the trial centres.  And if it‟s not a trial centre you can‟t actually 
recruit, you can‟t actually counsel for those trials.  The surgeon is not allowed to do it, so – 
 
Do you think every patient who is eligible for a sort of trial which is available at that 
time is, is being highlighted in the MDT?  Which is one of the functions of the MDT. 
 
No, because then you have to know.  You have to, you have to have surgeons and other 
clinicians there who are aware of the trial – 
 
Aware of the trial. 
 
And not all, not all surgeons and other clinicians, you know, the oncologists.  And the 
oncologists are better than the surgeons actually, often.  They know their own trials for 
advanced disease.  And I think surgeons are not great unless they‟re in, in an academic 
institution.  Even the academic institutions are very variable, depending on how interested the 
surgeon is in trials.  So I think it‟s very, it, it depends on the individuals, so. 
 
And there are cases forgotten? 
 
Forgotten? 
 
Well, about the trial – 
Yeah. 
 
Let‟s say nobody, nobody remembers the trial? 
 
Yeah, nobody mentions, yeah, nobody remembers. 
 
Well, don‟t you think we should, we should dedicate this job, or it‟s one of the duties of 
a research nurse to do this? 
 
It is a duty of the research nurse, but then not every centre is going to have a research nurse 
because that‟s an extra salary.  In these, in NHS, I don‟t think it‟s going to happen.  But it 
may be that you have one research nurse and, if you have a teleconference, then she‟s 
available to the three or four hospitals at that conference, teleconference. 
 
She knows in advance who‟s? 
 
She knows advance, in advance.  And you only need one nurse then, who‟s… but then the 
problem is, even if you want to recruit them for the trial, the patient has to go to one of the 
centres which is designated for the trial to get counselled for it. 
 
Oh, that‟s another problem? 
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So for example, if a patient at Homerton is suitable for a trial, they would have to come to 
UCH to get counselling for it.  So are they really going to make that trip to get counselled for 
the trial, because there‟s no-one at Homerton who would be allowed to counsel them for the 
trial. 
 
Well, a very significant reason. 
Mmmm. 
Last question, do you think the patient should be involved in the MDT, like there are a 
few, in the (inaudible 00:22:23), there are a few calls that the patient should be involved 
in the decision making, well, at the same time? 
 
No, I don‟t think so.  I think it would make the MDT… it, it wouldn‟t be practical.  I think 
mainly for practical reasons, it just, the, that would be, that would happen in an ideal world.  
And it really does happen, when you make the decision at the MDT and you go and counsel 
them for it, then you‟re having that discussion.  But if they were present for the MDT, the, 
practically, the MDT would take all day.  It would be ideal, but it‟s not going to happen.  
 
So (inaudible 00:22:58) is not, it‟s not going to be practical.  Okay, great, do you have 
any questions at all, or you, do you like to add anything? 
 
No, I think I‟ll (overspeaking) 
 
Oh great, thanks very much. 
 
[End of Transcript] 
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Appendix 5: An email reply from NRES waiving the REC review for the online 
survey. 
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Appendix 6: The survey of the MDT coordinators 
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Appendix 7: The survey questionnaire for chapter 6: Srategies to improve the 
utility and efficiency of the urology MDT meeting 
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